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Abstract
DIET-RELATED CHANGES IN SENSITIVITY TO THE PHARMACOLOGICAL
EFFECTS OF DELTA-9-TETRAHYDROCANNABINOL
By Mayo Jerry Wright Jr., M.S.
A dissertation submitted in partial fulfillment of the requirements for the degree of
Doctor of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2009
Major Directors:
Jenny L. Wiley, Ph.D.
Associate Professor, Pharmacology and Toxicology
Joseph H. Porter, Ph.D.
Professor, Psychology

Recent evidence suggests that sustained consumption of a high-fat diet is
associated with reduced CB1 receptor expression in some brain areas. Many of the
neuromodulatory functions of endogenous cannabinoids are mediated by the CB1
receptor. The CB1 receptor also mediates the behavioral and physiological effects of 9tetrahydrocannabinol (9-THC), the primary psychoactive constituent of marijuana.
While high-fat diets are associated with region-specific changes in CB1 receptor
expression, it is not clear whether such changes are behaviorally relevant. To that end,
separate groups of male and female rats were placed on either a high-fat diet or a standard
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diet. Cannabinoid function was determined in a triad of measures (e.g., hypothermia,
gross locomotion, time on bar apparatus) at postnatal day 30 (PD30), PD44, PD68 and
PD114. These age points respectively correspond to rodent models of early adolescence,
late adolescence, early adulthood and full maturity in humans. Male rats were also tested
at PD37 and PD61. Subsequently, the antinociceptive properties of 9-THC and the effect
of 9-THC on food intake were also measured. After 38 days, female rats maintained on
a high-fat diet were significantly less sensitive to the psychomotor effects of 9-THC
than were the female rats maintained on the control diet. These diet-related differences
persisted into full maturity. Female rats maintained on a high-fat diet were also less
sensitive to changes in food intake caused by 9-THC than were female rats maintained
on the control diet. In contrast, the hypothermic effects of 9-THC were not differentially
affected by the type of diet consumed. Likewise, female rats maintained on a high-fat diet
exhibited tail-flick latencies that were indistinguishable from those of female rats
maintained on the control diet. With two minor exceptions, and in sharp contrast to
female rats, sensitivity to the pharmacological effects of 9-THC was not differentially
affected by the type of diet in male rats. In short, female rats maintained on a high-fat diet
appeared to be cross-tolerant to the psychomotor and hyperphagic effects of 9-THC
while male rats maintained on a high-fat diet exhibited responses to 9-THC that were
virtually indistinguishable from control animals.

x

Introduction
The Endogenous Cannabinoid System
The endogenous cannabinoid, or endocannabinoid, system is a lipid-based
signaling system that is composed of two known ligands, several putative ligands, at least
two types of G-protein-coupled receptors, a pair of hydrolytic enzymes, and may also
include a dedicated reuptake transporter. Endocannabinoids act at the CB1 receptor to
modulate neural impulses in the central nervous system, to modulate activity in the
reproductive system and the gastrointestinal and also play an important role in regulating
lipogenesis (Di Marzo et al., 1998; Cota et al., 2003). The CB2 receptor is found
primarily in immune cells (Munro et al., 1993; Galiegue et al., 1995) where it modulates
immune function (Schatz et al., 1997; Cabral, 2001). Recent reports suggest that CB2
receptors are also detectable in neurons (Brusco et al., 2008), but these data remain
controversial and the function of these receptors, if present, is unclear.
Endocannabinoids are most commonly synthesized in the postsynaptic density of
GABAergic and glutamatergic neurons (Rodriguez de Fonseca et al., 2005). Once
synthesized, endocannabinoids can traverse backward across the synaptic cleft to inhibit
presynaptic neural impulses (Wilson and Nicoll, 2001). Endocannabinoids may attenuate
inhibitory signals in some brain areas by limiting the release of the inhibitory
neurotransmitter gamma-aminobutyric acid (GABA; Maneuf et al, 1996; Wilson et al.,
2001) through a process known as depolarization-induced suppression of inhibition (DSI;
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Pitler and Alger, 1994; Kreitzer and Regehr, 2001A). During DSI, endocannabinoids act
to reduce calcium-ion uptake at the axon terminals of the presynaptic neuron, which
suppresses the binding of vesicles to the cell membrane and the subsequent release of
GABA into the synapse. Similarly, endocannabinoids may produce depolarizationinduced suppression of excitation (DSE) by inhibiting the release of the excitatory
neurotransmitter glutamate (Kreitzer and Regehr, 2001B). Endocannabinoids also appear
to inhibit the action of dopaminergic (Giuffrida et al, 1999) and serotoninergic neurons
(Best and Regehr, 2008). In keeping with their neuromodulatory role, endocannabinoids
are only synthesized when and where they are needed. The interval during which
endocannabinoids exert their physiological influence is brief because they are degraded
rapidly.
Though CB1 receptors are distributed widely throughout the brain, they are
densely packed in the cerebral cortex, striatum, globus pallidus, substantia nigra, nucleus
accumbens, hippocampus, and the cerebellum (Herkenham et al., 1990; Bliss and
Collingridge, 1993; Collins et al., 1994; Miller and Walker, 1995; Herkenham et al.,
1991; Herkenham et al., 1990; Rodriguez de Fonseca; 1998). The list of functions
associated with these brain areas (e.g., cognition, locomotor function, learning and
memory, reward, coordination and balance) highlight the physiological significance of
the endocannabinoid system. Endocannabinoids are also known to play an important role
in energy balance and metabolism. Although CB1 receptor densities are relatively low in
the hypothalamus (Fitton and Pertwee, 1982; Mattes et al., 1994), activation of the G-
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proteins that are coupled to CB1 receptors in the hypothalamus is highly efficient
(Breivogel et al., 1997).
Elucidation of the endocannabinoid system began in earnest with the isolation of
(-)9-tetrahydrocannabinol (9-THC), the primary psychoactive constituent of Cannabis
sativa (Gaoni and Mechoulam, 1964). For two decades, researchers worked to
understand the behavioral pharmacology of cannabinoids, all while lacking a wellunderstood mechanism of action. Some thought that cannabinoids, which are highly
lipophilic, could exert their affects by passive diffusion into neurons or by altering the
fluidity of the cell membrane (Leuschner et al., 1986).
The array of physiological effects produced by cannabinoids and the observation
that at least some cannabinoids displayed high-affinity for a binding site in the brain,
however, led many to believe that cannabinoid pharmacology must be receptor-mediated
(Harris et al., 1978; Nye et al., 1985; Mechoulam, 2006). For instance, the (-)isomer of
the cannabinoid agonist 11-hydroxy-delta 8-tetrahydrocannabinol-dimethylheptyl
(HU210) is at least several hundred times more potent than the (+)-isomer (HU211; Little
et al., 1989). This disparity in potency between optical isomers is indicative of
stereospecific binding at a receptor (Soudjin, et al., 2003).
Shortly after cannabinoid receptors were discovered in the brain, (Devane et al.,
1988), the receptor itself was cloned (Matsuda et al., 1990). Initially identified as SKR6,
the newly cloned receptor interacted cannabinoid ligands (i.e., 9-THC, CP55, 940) but
failed to interact with other ligands (i.e., bradykinin, angiotensin II, cholecystokinin) in
radioligand binding assays. This newly discovered receptor also produced dose-
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dependent changes in forskolin-stimulated accumulation of cAMP when stimulated with
9-THC and CP55, 940. These drug-induced changes in cAMP concentration occurred in
a stereoselective manner; the (+)isomers of 9-THC and CP55, 940 were much less
potent than the (-)isomers. Importantly, SKR6 was found to be distributed in the same
brain regions as the previously identified cannabinoid receptor.
Cannabinoid receptors belong to a class of receptors called G-protein-coupled
receptors (GPCRs). GCPRs are metabotropic receptors and, as such, exert their
physiological influence through a series of second-messengers (i.e., cAMP, PIP3;
Rodbell, 1997). These receptors and their downstream effectors regulate a complex series
of downstream reactions in a process collectively referred to as “signal transduction”
(Rodbell, 1995).
In an inactive state, the G-protein complex consists of a receptor with 7transmembrane domains, a complex of 3-subunits (, , and ) that is bound to the
cytosolic face of the cell membrane and a molecule of guanosine diphosphate (GDP;
Rodbell, 1995; Rodbell, 1997). When a ligand binds to the receptor, the complex is
activated and undergoes a conformational change that decreases the affinity of the G
subunit for GDP and increases the affinity of the G subunit for GTP. When GTP binds
to the G subunit, another conformational change reduces the affinity of the G subunit
for the G subunits. The G-GTP complex then dissociates from the rest of the GPCR
complex. Once dissociated, the G-GTP complex activates the appropriate second
messenger. In the process of activating the second messenger, the G-GTP complex is
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dephosphorylated to form a G-GDP complex. Once bound to GDP, the G subunit
again joins the G subunits and the GPCR returns to an inactive state.
The newly cloned CB1 receptor was useful in the effort to isolate an endogenous
cannabinoid ligand. The first known endocannabinoid was identified from porcine tissue
samples (Devane et al., 1992) and became known as “anandamide”. Anandamide is a
contraction of the Sanskrit word for “bliss” (ananda) and the term for the central chemical
moiety of the associated structure (an amide). Anandamide is a derivative of arachidonic
acid and is formally known as N-arachidonyl ethanolamine (AEA). The phospholipid
precursor to anandamide, N-phosphatidyl ethanolamine (NAPE), is produced when an
enzyme known as N-acyltransferase transfers an arachidonic acid molecule to a molecule
of phosphatidylcholine (Cadas et al., 1996; Piomelli, 2003). The production of NAPE is
calcium-dependent and is regulated by cAMP. The enzymes that cleave anandamide from
NAPE include N-phosphatidyl ethanolamine phospholipase D (NAPE-PLD), but other
phospholipase enzymes likely play a role in anandamide synthesis (Leung et al., 2006).
Anandamide is an agonist at CB1 receptors (Mechoulam and Fride, 1993) and has
a pharmacological profile similar to that of 9-THC (Crawley et al., 1993; Weidenfeld et
al., 1994; Williams and Kirkham, 1999). The CB1 receptor is typically coupled to Gi/Go
proteins. As such, CB1 receptor stimulation by an agonist like anandamide inhibits the
formation of cAMP and, consequently, reduces the activity of phosphokinase A (PKA).
The downstream effects of reduced PKA activity include diminished phosphorylation of
a variety of target enzymes. Recent evidence suggests that the highly lipophilic nature of
endocannabinoids allows them to bind to and activate cannabinoid receptors from within
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the lipid bilayer unlike hydrophilic ligands that must bind while being stabilized in the
polar extracellular space (Nebane et al., 2008).
Several years after the identification of anandamide, a second endocannabinoid,
2-arachidonoylglycerol (2-AG), was identified (Mechoulam et al., 1995). While
anandamide is now thought of as a partial agonist at the CB1 receptor, 2-AG is generally
regarded as a full-agonist and is found in much higher concentrations in the brain than
anandamide (Gonsiorek et al., 2000; Sugiura et al., 1995; Stella et al., 1997). Despite the
similarity of the pharmacological profile of anandamide and 2-AG, they are produced
through discrete synthetic pathways.
The pathways that produce 2-AG are robust because of the variety and
redundancy of the precursors and enzymes that can be employed. The primary precursors
of 2-AG are phosphatidylinositol bisphosphate (PIP2), phosphatidylinositol (PI) or
phosphatidylcholine (PC), all of which are phospholipids that are commonly found in the
cell membrane (Sugiura et al., 2006). These precursors can be converted to 2-AG by the
coordinated action of phospholipase A1, phospholipase C and/or diacylglycerol lipase
(Sugiura et al., 1995). In an alternate pathway, phosphatase enzymes can convert the
conjugate of arachidonic acid and lysophosphatidic acid (2-arachidonyl LPA) into 2-AG
(Nakane et al., 2002).
Early on, it became apparent that the duration of action of endocannabinoids is
limited because the compounds are rapidly hydrolyzed (Deutsch and Chin, 1993). The
primary enzyme that degrades anandamide is called fatty-acid amidohydrolase (FAAH;
Cravatt et al., 1996). FAAH, which belongs to a class of enzymes called serine
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hydrolases, is promiscuous and can hydrolyze whole classes of long-chain
acylethanolamines and primary amides. FAAH is primarily found on the membranes of
cytoplasmic organelles (i.e., mitochondria, smooth endoplasmic reticulum) and the
intracellular face of the plasma membrane in postsynaptic neurons (Gulyas et al., 2004).
It has been hypothesized that FAAH held the capacity to degrade 2-AG as well as
anandamide, but recent work suggests that FAAH is not an important contributor to 2-AG
hydrolysis in the brain (Blankman et al., 2007).
The enzyme that is primarily responsible for 2-AG hydrolysis is called
monoacylglycerol lipase (MAGL; Dinh et al., 2002). MAGL has more substrate
specificity that FAAH and can only hydrolyze a subset of monoacylglycerols (Matias et
al., 2006). MAGL also seems to function presynaptically (Gulyas et al., 2004), while
FAAH seems to function as a postsynaptic enzyme. Because the pathways that produce
endocannabinoids are not under unified control and because the enzymes that degrade
endocannabinoids are found in distinct subcellular regions, some have suggested that
anandamide and 2-AG play unique roles in the endocannabinoid system (Chevaleyre et
al., 2003).
Pharmacological Effects of Cannabinoids
A cluster of four tests conducted in mice, commonly referred to as the “Martin
Tetrad”, are used to probe for the signature effects of cannabinoid drugs. The tetrad
includes measures of transient hypothermia, antinociception, locomotor inhibition and
catalepsy-like behavior (Loewe, 1946; Hardman et al., 1971; Smith et al., 1994;
Chaperon and Theibot, 1999).
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In rodents, both anandamide and 9-THC can reduce rectal temperature by in
excess of 5oC (Smith et al., 1994; Hosko et al., 1981). Other drugs with cannabinoid
activity (i.e., CP55,940, WIN 55212-2) have also been reported to produce similar
hypothermic responses (Compton et al., 1992; Rawls et al., 2007). The amount
cannabinoid-induced hypothermia is dose-dependent and is affected by the route of
administration. Recent evidence suggests that inhibitors of endocannabinoid hydrolysis
can also reduce body temperature significantly (Burston et al., 2008; Long et al., 2009).
The mechanism by which cannabinoids reduce body temperature is unclear, but
the amount and duration of hypothermia may be regulated in the anterior hypothalamus
and the caudal portion of the brainstem (Schmeling and Hosko, 1976; Hosko et al.,
1981). While cannabinoids induce hypothermia, this transient reduction in body
temperatures may involve receptors other than CB1. For example, AM404, a drug that
elevates endocannabinoid levels in the synapse, produces a hypothermic response in mice
that can be blocked by a vanilloid (TRPV1) receptor antagonists (Rawls et al., 2006).
Similarly, hypothermia produced by cannabinoid agonists can be attenuated by
nociceptin/orphanin FQ (N/OFQ) receptor antagonists (Rawls, et al., 2007).
Cannabinoids also produce catalepsy-like behavior in mice and rats (Grunfeld and
Edery, 1969). Catalepsy is characterized by muscle rigidity and the maintenance of a
fixed posture, even if the posture might appear to be uncomfortable (Sanberg et al.,
1988). Catalepsy induced by 9-THC may involve diminished 5-HT(2A) and 5-HT(1A)
signaling in the nucleus accumbens (Sano et al., 2008; Egashira et al., 2007; Egashira et
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al., 2006). This reduction in serotonergic signaling is likely related to the inhibitory
activity of 9-THC at glutamatergic neurons.
In addition to inducing catalepsy-like behavior, cannabinoids also inhibit
locomotion at moderate and high doses. Varying degrees of immobility are observed
after treatment with a variety of cannabinoids (i.e., anandamide, 9-THC; Rodreiguez de
Fonseca et al., 1998). Evidence derived from experiments with non-human primates
suggests that cannabinoid-induced locomotor inhibition may be related to decreased
dopaminergic signaling at dopamine D2 neurons (Meschler et al., 2000). In these studies,
locomotor activity was significantly inhibited when a sub-threshold dose of the CB1
agonist levontradol was combined with sub-threshold doses of quinelorane or pergolide,
both of which are dopamine D2 agonists. The dopamine D1 agonist SKF81297, however,
did not alter the relationship between levontradol and locomotor activity.
Evidence from rats corroborate the putative relationship between dopamine D2
receptors, cannabinoids and locomotor activity (Marcelllino et al., 2008). The
cannabinoid agonist CP55, 940 dose-dependently reduced the affinity of dopamine D2
receptor binding sites in membrane preparations derived from the dorsal and ventral
striatum of rat brains. Sub-threshold doses of CP55, 940 attenuated the locomotor
stimulation produced by quinpirole, a dopamine D2 agonist, in these same studies.
Cannabinoids are thought to produce antinociception by synergistically
interacting with opioid receptors and 2-adrenoreceptors (Cichewicz and McCarthy,
2003; Tham et al., 2005; Cox et al., 2007). Evidence from mice suggests that
cannabinoid receptors and kappa opioid receptors are co-localized in the dorsal horn of
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the spinal cord and interact to modulate the transmission of noxious stimuli from sensory
neurons (Smith et al., 1994; Reche et al., 1996). Blockade of CB1 receptors by AM281
has been shown to produce a compensatory elevation of kappa opioid receptors in the
spinal cord of mice (Saez-Cassanelli et al., 2007). In those same experiments, AM281induced antinociception was reversed by nor-binaltorphimine, a kappa opiod antagonist.
Additionally, cannabinoid receptors are thought to interact with mu opioid receptors in
the brain are thought to reduce the perception of noxious stimuli (Reche et al., 1996). In
tail-flick and hot plate tests with mice, sub-threshold doses of morphine augmented the
antinociceptive properties of 9-THC in a synergistic fashion. This effect was blocked by
the mu-opiod receptor antagonist -funaltrexamine as well as a kappa-opioid receptor
antagonist and a CB1 receptor antagonist.
Animal Models of Adolescence and the Development of the Endocannabinoid System
Adolescence and puberty are temporally-related events, though each has a distinct
definition. Puberty refers to the attainment of sexual maturity (Graber and Brooks-Gunn,
1998) while adolescence is the gradual period of transition from childhood to adulthood
(Pickles et al., 1998). Because the onset of adolescence cannot be defined by any single
biochemical, endocrine or neuroanatomical milestone, it is difficult to characterize the
precise timing and duration of adolescence in physiological terms (Rosenblum, 1990).
Instead, adolescence can be characterized by age-specific behaviors such as
increased risk-taking and social interaction. The behavior of adolescent animals is also
highly peer-directed and is characterized by novelty-seeking. In rats, adolescent-typical
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behavior is commonly observed between postnatal day 28 and postnatal day 42 (Spear,
2000).
The behavioral changes associated with adolescence do not seem to be
significantly related to changes in gonadal hormonal levels (Brooks-Gunn et al., 1994).
Instead the maturational changes in the brain that occur around postnatal day 28-42
contribute to the age-specific behavioral characteristics of adolescence (Spear, 2000).
During adolescence many brain regions (i.e., prefontal cortex) and brain systems (i.e.,
dopaminergic system) are undergoing important changes (Van Eden et al., 1990).
Another system undergoing such change is the endocannabinoid system.
Endocannabinoids play an important role in neurological development
(Fernandez-Ruiz et al., 1999) and, in rodents, the endogenous cannabinoid system
continues to mature well after birth (Rodriguez de Fonseca et al., 1993; Belue et al.,
1995). There are subtle sex-differences in the timing of CB1 receptor development, but
both sexes express maximum CB1 receptor densities between postnatal day 30 and
postnatal day 40. As adolescence draws to a close (postnatal day 40), male rats express
greater CB1 receptor density in the midbrain than females and that trend continues into
early adulthood, although CB1 receptor density is similar in other brain areas (Rodriguez
de Fonseca et al., 1993). By adulthood (postnatal day 90), CB1 receptor densities
stabilize in all brain areas (Belue et al., 1995). Some data suggest CB1 receptor density
declines in a region specific manner (e.g., cerebellum, hypothalamus, hippocampus;
Berrendero et al., 1998) as rats age beyond two years, but there is also evidence that
whole brain receptor densities do not change significantly up to thirty-two months of age
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(Belue et al., 1995). While the CB1 receptor densities change during maturation, receptor
affinity does not appear differ dramatically during development (McLaughlin et al.,
1994).
While CB1 receptors mature slowly during the postnatal period, behavioral data
suggest that the endocannabinoid system reaches functional maturity during adolescence.
There is some evidence that very young rodents (postnatal day 6 though postnatal day 23)
exhibit little locomotor inhibition or antinociception after treatment with anandamide or
9-THC (Fride and Mechoulam, 1996A; Fride and Mechoulam, 1996B). This is relevant
because changes in locomotion and antinociception, along with hypothermia and
catalepsy-like behavior, are hallmarks of cannabinoid pharmacology (Smith et al., 1994).
By the onset of adolescence (postnatal day 28), however, this pattern of response changes
(Schramm-Sapyta et al., 2007; Wiley et al., 2008). In adult rodents, low doses of 9 THC can stimulate locomotion (Wiley et al., 2008), while larger doses of cannabinoid
agonists typically inhibit locomotion and induce antinociception (Fride and Mechoulam,
1996B). It is not yet clear, however, whether these age-related differences in cannabinoid
pharmacology are linked to changes in CB1 receptor expression or sensitivity, cell
signaling, cannabinoid pharmacokinetics or some other mechanism.
Perhaps related to the slow maturation of the endocannabinoid system, there
seems to be a vulnerable developmental period in rodents during which cannabinoid
exposure produces long-lasting behavioral alterations, especially in behavior involving
cognitive tasks (Stiglick and Kalant, 1985). Other work in rodents shows that chronic
pubertal treatment with cannabinoids produces long-lasting reductions in the motivation

12

to work for a food reward, but similar treatment during adulthood does not produce the
same effect (Schneider and Koch, 2003). There is complementary evidence from humans
that long-lasting attentional deficits may be related to cannabis abuse that began before
age sixteen (Ehrenreich et al., 1999).
Sex Differences in Cannabinoid Effects
There is evidence that males and females metabolize Δ9-THC differently.
Experiments with liver cultures suggest that female rats overwhelmingly metabolize Δ9THC to 11-hydroxy-9-THC (Narimatsu et al., 1991), a potent psychoactive compound
(Lemberger et al., 1973). In contrast, male rats metabolize Δ9-THC to a variety of
compounds (including 11-hydroxy-9-THC). This is significant because many of the
other metabolites of Δ9-THC produced in male rats are less psychoactive than 11hydroxy-9-THC. These observed ex vivo differences in the metabolism of Δ9-THC are
corroborated by the observation that female rats have higher peak brain levels of 11hydroxy-9-THC than do male rats after intraperitoneal administration of Δ9-THC (Tseng
et al., 2004). Importantly, blocking the metabolism of 9-THC eliminates sex-differences
in antinociception in rats.
Human females have been shown to achieve higher maximal blood concentrations
of 9-THC and do so more rapidly than males after oral consumption of cannabis
(Nadulski et al., 2005). However, 9-THC can accumulate in fatty tissues (Nahas et al.,
1981), so it is possible that sex-related differences in body composition play a role in the
bioavailability of 9-THC. In contrast, other studies with humans indicate few differences
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in the degree to which men and women metabolize Δ9-THC to 11-hydroxy-9-THC,
regardless of whether the drug was delivered intravenously or by mouth (Wall et al.,
1983).
While sex-related differences in cannabinoid pharmacokinetics have been
documented, there are also important sex-related differences in cannabinoid
pharmacodynamic. For example, there may be sex-related differences in the degree to
which cannabinoids alter neuronal signaling in the arcuate nucleus, a brain area that
controls homeostatic function like food intake. There is some evidence that rapidlyinactivating, voltage-gated potassium channels (A-type K+ channels) in the
hypothalamus are inhibited by cannabinoids to a greater degree in female guinea pigs
than in male guinea pigs (Tang et al., 2005). The CB1 receptor agonists WIN55,212 and
ACEA induced a rightward shift in the inactivation curve for these currents in females,
but not in males. A rightward shift in this curve suggest that when treated with
WIN55,212 or ACEA, more voltage-gated potassium channels are inhibited in females
than in males. Consequently, a greater number of neuronal impulses are inhibited. The
inhibitory effect of cannabinoids on these potassium channels were reversed after the
application of a CB1 antagonist.
There are also important sex-related behavioral differences in cannabinoid
pharmacology. When these sex differences are detected, females tend to be more
sensitive to the pharmacological effects of cannabinoids than males (Cohn et al., 1972).
In an experiment with humans, females treated with Δ9-THC exhibited a greater drop in
cerebral blood velocity and blood pressure after standing (orthostatic hypotension) and
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reported being more dizzy than males, even though the plasma levels of Δ9-THC were
indistinguishable (Mathew et al., 2003). Cannabinoids may also induce antinociception
and inhibit locomotion at lower doses in female rats than male rats (Tseng and Craft,
2001).
It is also interesting to note that chronic exposure to Δ9-THC during adolescence
exaggerates the relationship between nutritional status and motivation to work for a food
reward as indexed by progressive-ratio breakpoints (Wright and Wiley, unpublished
data). Unlike males, female rats continued to exhibit elevated progressive-ratio
breakpoints even when they were tested at 100% of their pre-testing bodyweight. This
observation suggests that the food reward used in these experiments may be a more
efficacious reinforcer in female rats than in male rats
High-Fat Diets and the Endogenous Cannabinoid System
The endocannabinoid system is a lipid-based signaling system and
endocannabinoid levels appear to be influenced by the lipid content of the diet. More
specifically, the type and quantity of polyunsaturated fatty acids (PUFAs) found in the
diet can directly influence the levels of endocannabinoid ligands in the body (Berger et
al., 2001; Watanabe et al., 2003). When mice and piglets are fed diets enriched with
omega-6 polyunsaturated fatty acids, brain levels of anandamide and 2-AG increase
significantly. High levels of omega-6 polyunsaturated fatty acids are commonly found in
corn oil, soybean oil and canola oil (Rodriguez-Cruz et al., 2005).
Diets rich in omega-6 polyunsaturated fatty acids may increase endocannabinoid
levels by providing additional substrate for FAAH, an enzyme that degrades anandamide
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(Matias et al., 2006). As previously mentioned, FAAH lacks the kind of substrate
specificity that is characteristic of MAGL (Dinh et al., 2002). As such, FAAH has been
shown to hydrolyze the amide bond of not only anandamide, but also several other
common amines formed from long-chain fatty acids (Schmid et al., 1985; Ueda et al.,
1995). Interestingly, chocolate contains two such fatty-acid amides (N-oleoythanolamine
and N-linoleoylethanolmine) that have been shown to inhibit the hydrolysis of
anandamide in brain cells, possible by acting as a substrate for FAAH (Di Tomaso et
al.,1996).
Even short-term consumption (e.g., 1 week) of diets rich in unsaturated fatty acids
can elevate brain levels of long-chain fatty acids (N-acylethanolamines) as well as
endocannabinoids (Artmann et al., 2008). The rats used in this study were fed diets rich
in either monounsaturated fats (i.e., olive oil) or polyunsaturated fats (i.e., safflower oil).
A diet rich in safflower oil may produce elevated levels of N-oleoythanolamine (OEA),
N-linoleoylethanolamine (LEA) and 2-AG, while a diet rich in olive oil may also produce
elevated brain-levels of anandamide as well.
There is some evidence that the density of CB1 receptors in some brain regions
increases soon after mice are placed on a high-fat diet, but then CB1 density declines after
sustained consumption of that diet (South and Huang, 2008). After 3 weeks, animals on
the high-fat diet displayed elevated CB1 receptor density in the medial and ventral
anterior olfactory nucleus, the agranular insular cortex and the hypothalamus when
compared to animals maintained on a low-fat, high carbohydrate diet.
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The increase CB1 receptor density among the mice fed a high-fat diet was
correlated with an increase in plasma leptin in the hypothalamus. Leptin is a circulating
hormone released primarily by white adipose tissue (Zhang et al., 1994) that acts in
rodents via hypothalamic receptors to inhibit feeding and increase energy-expenditure
(Jequier, 2002). There is also an inverse relationship in the hypothalamus between
exogenously administered leptin and both anandamide and 2-AG (DiMarzo et al., 2001).
When mice were maintained on the high-fat diet for 20 weeks, they became
obese, hyperphagic and displayed decreased CB1 receptor density in several rewardrelated brain areas (i.e., substantia nigra, ventral tegmental area). Though the brain
endocannabinoid levels were not measured in these experiments, these results are
certainly consistent with increased endocannabinoid signaling after sustained
consumption of a high-fat diet.
Other evidence suggests that mice maintained on a high-fat diet have increased
hepatic anandamide levels, perhaps because of the competitive inhibition of FAAH by
fatty-acid amides (Osei-Hyiaman et al., 2005). Animals maintained on a high-fat diet also
had dramatically diminished levels of FAAH activity when compared to controls, even
though all the animals appeared to be synthesizing the same level of enzyme.
While endocannabinoid levels appear influenced by the types and quantities of
polyunsaturated fats in the diet, high-fat diets may also be related to changes in CB1
receptor density. When mice were maintained on a high-fat diet long enough to induce
obesity, CB1 receptor densities in the hippocampus, nucleus accumbens and
entopeduncular nucleus declined (Harrold et al., 2002). The researchers involved in this
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experiment produced their high-fat diet by supplementing normal rodent chow with
Nestle condensed milk (PUFA content ranging 6%-36%; Harrold et al., 2002). While the
fat composition of the milk used in these experiments varied significantly, two-thirds of
the polyunsaturated fatty acids in condensed milk are usually of the omega-6 variety
(USDA National Nutrient Database for Standard Reference, 2005).
In mice, sustained consumption of a high-fat diet that also contains elevated levels
of cholesterol has been shown to reduce CB1 receptor density in the striatum and the
hypothalamus (Hayakawa et al., 2007). Curiously, chronic food restriction had the
opposite effect. In these experiments, mice were divided into 3 groups: those receiving a
normal diet, those receiving a restricted portion of a normal diet and those receiving a
high-fat, cholesterol-enriched diet. After 6 weeks, both serum and brain cholesterol levels
were determined and Western blots were used to determine the expression level of CB1
receptors in the cortex, the striatum and the hypothalamus.
As expected, serum cholesterol levels significantly increased in the group fed the
high-fat diet. Conversely, striatal cholesterol levels significantly decreased and there was
also a non-significant trend for cholesterol levels in the hypothalamus to decrease in that
same group. Importantly, the level of CB1 receptor expression in the striatum also
decreased significantly in the group that was fed the high-fat diet.
There is evidence that altering dietary fat intake can affect the composition of the
cell membrane in general and, more specifically, change the composition of lipid rafts
(Siddiqui et al., 2007). Lipid rafts are small segments of the cell membrane that contain
high-levels of cholesterol and sphingolipids (Barnett-Norris et al., 2005). These small
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pools of densely-packed saturated lipids move freely among the more loosely-packed
unsaturated lipids that compose the cell membrane. Lipid rafts may permit some types of
receptor proteins to coalesce (Melkonian et al., 1999) and increase signal transduction
efficiency in the process (Moffett et al., 2000). It appears that lipid rafts influence
binding and signaling at CB1 receptors (Barnett-Norris et al., 2005) and that the
cholesterol content of the lipid raft may modulate the degree to which the receptor is
activated by AEA (Bari et al., 2005).
Interestingly, while high-fat diets decrease CB1 receptor density in some areas of
the brain, it may also increase CB1 receptor densities in the liver (Osei-Hyiaman, et al,
2005). While it is not yet clear why these differences CB1 receptor expression occur,
they may be reflective of the peripheral role of cannabinoids as modulators of lipogenesis
(Osei-Hyiaman et al., 2005, Loftus et al., 2001, Kim et al., 2002).
While a mechanism for these changes in leptin, anandamide and CB1 receptors
has not yet been demonstrated, it may be related to the various and sometimes disparate
actions of endocannabinoids. Taken together, these results suggest that diet-induced
obesity results in elevated levels of circulating leptin. In response to increased leptin
levels, endocannabinoid synthesis declines in the hypothalamus. This diminished
endocannabinoid tone results in a short-term increase in CB1 receptor expression. If the
high-fat diet is maintained for an extended period of time, however, anandamide levels
rise because of the competitive inhibition of FAAH, or for some other yet unknown
process. In response to the now elevated endocannabinoid tone, CB1 receptor expression
is downregulated.
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The Development of Cannabinoid Tolerance
In vitro studies show that chronic treatment with cannabinoid agonists produces
CB1 downregulation (i.e., loss of binding sites) and desensitization (i.e., loss of G-protein
effector activity; Sim-Selley, 2003). The endocannabinoid system has a great deal of
adaptive capacity and significant cannabinoid tolerance can develop, even with
intermittent exposure to cannabinoids (Wiley et al., 1993). The changes in CB1 receptor
density that occur after repeated exposure to exogenous cannabinoids like WIN 55,212-2
or 9-tetrahydrocannabinol (Sim-Selley and Martin, 2002) are similar to the changes in
CB1 receptor density that are associated with the sustained consumption of a high-fat diet
(Harrold et al, 2002).
Cannabinoid tolerance can also be measured in vivo. Cannabinoids transiently
reduce body temperature (hypothermia), suppress spontaneous activity, induce catalepsy
(Wiley and Martin, 2003) and increase food consumption (hyperphagia; Wiley et al.,
2005). When animals are repeatedly treated with exogenous cannabinoids like 9tetrahydrocannabinol, hypothermia diminishes, levels of spontaneous activity return
toward the baseline, catalepsy wanes (Fan et al., 1994), and hyperphagia dissipates (Jarbe
and Di Patrizio, 2005).
Like most psychoactive drugs, cannabinoids can produce context-specific
tolerance through Pavlovian conditioning (Hill et al., 2004). The pharmacological effects
of cannabinoids serve as an unconditioned stimulus and the environment in which those
effects are experienced can serve as a conditioned stimulus. When the pharmacological
effects of a drug are repeatedly and exclusively paired with a particular environment (i.e.,

20

a behavioral pharmacology lab), context-specific (or behavioral) tolerance can develop.
In this phenomenon, the conditioned stimulus acquires the ability to elicit compensatory
responses that diminish the effects of the drug in question. Though some of the most
striking examples of context-specific tolerance involve opioids (Siegel, 1976), similar
results can be observed with repeated exposure to any psychoactive drug under the
correct conditions.
A nascent body of evidence suggests that sustained consumption of a high-fat diet
is related to region-specific reductions of CB1 receptor expression in the brain. This
reduction in CB1 receptor density is similar to changes that are observed in rodents made
tolerant to cannabinoids. It is not clear, however, whether the receptor changes observed
after sustained consumption of a high-fat diet are behaviorally or physiologically
relevant. Because of the nature of these CB1 receptor changes, it is hypothesized that rats
maintained on a high-fat diet will be less sensitive to some or all of the pharmacological
effects of 9-THC. Because of sex-related differences in cannabinoid responses, it is also
hypothesized that diet-related behavioral and physiological in cannabinoid pharmacology
will be more evident in female rats than in male rats.
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Method
Animals
All of the research in this proposal was conducted on male and female Long-Evans rats
(Harlan Labs, Dublin, Virginia). All rats were single-housed in 11” X 17” X 8” Makrolon
cages in a temperature-controlled (20oC–22oC) environment with 12-hour light and dark
cycle (lights on at 6:00 am). Water and the appropriate type of rodent chow were freely
available in the home cages. Food consumption and bodyweight were recorded twice
each week and average daily food intake and weight change was calculated. Each of
these studies was carried out in accordance with the Guide for the Care and Use of
Laboratory Animals (National Research Council, 1996) and was approved by the
Virginia Commonwealth University Institutional Animal Care and Use Committee.
Virginia Commonwealth University is an AAALAC accredited institution.
Diet
The high-fat diet used in these experiments was made by enriching standard
rodent chow (Harlan Teklad Diet LM-485) with corn oil. The standard rodent chow was
soaked in room-temperature corn oil (20oC-22oC) for 24 hours before being drained and
dried on clean paper towels. Once prepared, the diet was sealed in plastic bags
immediately and stored at 4oC for a duration of no more than 7 days. Probe trials have
determined that when soaked for 24 hours in room-temperature corn oil, the resulting diet
contained 4.63 kcal/g with 33.3% of those calories coming from fat (Fig. 1). This diet
was appropriate for these experiments because it was similar to diets used in related
experiments that were performed in other labs and because it contained levels of fat that
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are similar to the dietary intake of fat of the U.S. population (Kennedy et al., 1999).

Stability of Fat Content in Chow
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Figure 1. Fat content of high-fat diet. Unfortified chow derives 17% of digestible
calories from fat. After soaking in corn oil at room temperature (20oC-22oC) for 24
hours, fat content increases to 34.7% of digestible calories. Over the course of the
following 4 days, 13% of the absorbed fat leeches from the chow. By the 5th day after
soaking, fat content stabilizes. The average percentage of calories derived from fat
over the shelf life of the food (7 days) is 33.3%.
In contrast, rats fed the control diet (Harlan Teklad Diet LM-485; 3.75 kcal/g)
derived 17% of their caloric intake from fat. The food for the control animals was kept in
a sealed container that was maintained at room temperature (20oC-22oC) until dispensed
into the feeding hopper in the home cage. In order to control for inter-group differences
in the freshness of the food, the standard chow was replenished at the same rate as the
high-fat chow (e.g., once every 7 days).
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Drugs
Delta-9-THC was obtained from the Drug Supply Program of the National
Institute on Drug Abuse and dissolved in a solution of Tween 80 (7.8%) and
physiological saline (92.2%). All injections of 9-THC were administered
intraperitoneally at a volume of 1 ml/kg, with the exception the 70 mg/kg dose. The 70
mg/kg dose was derived from a 35 mg/ml solution and was administered at a volume 2
ml/kg.
Apparatus
Clear plastic cages (44 cm in length X 22.5 cm in width X 20 cm in height)
covered with ventilated lids and housed in sound-attenuating cabinets were used as
locomotor chambers. The chambers did not contain bedding and were cleaned with an
alcohol solution between sessions. The sessions were conducted in near dark conditions
as the cabinet doors were closed. A cage rack system with photocell beams along the xaxis (8 beams) and y-axis (4 beams; Lafayette Instrument, Lafayette, IN) were placed
around each chamber and positioned 4.5 cm above the chamber floor. Locomotor activity
was measured as total number of beams broken during the 5-minute session.
A Traceable® digital thermometer (Control Company, Friendsville, TX) equipped
with a flexible, plastic-coated probe was used to measure rectal temperature. Probes
measuring 1.5 mm in diameter were used for determining temperatures in adolescent rats
(e.g., PD30 and PD44) and probes 3.5 mm in diameter were used for adult rats (e.g.,
PD68 and PD 114).
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The bar apparatus that was used to measure catalepsy-like behavior consisted of a
280-mm long bolt (12.5 mm in diameter) that was attached to a vertical frame by
eyebolts. The height of the bar was adjusted based upon the age of the rat (80 mm high at
PD30, 100 mm high at PD44, and 130 mm at PD68 and PD114). To reduce the influence
of extraneous stimuli, each bar apparatus was enclosed on the back, top and sides. The
cardboard enclosure was open in the front to permit access for the experimenter. Unlike
the locomotion sessions, which were conducted in near dark conditions, rectal
temperature and performance on the bar apparatus will be measured under normal indoor
fluorescent lighting conditions.
Procedure
Females. A group of female Long-Evans rats (n = 9), was fed a high-fat diet (4.63
kcal/g; 33% of calories from fat) beginning at postnatal day 30 (PD30). A separate group
of female Long-Evans rats (n = 9) was fed a control diet (3.75 kcal/g; 17% of calories
from fat) for the duration of these experiments. For female rats, cannabinoid activity was
assessed in a triad of measures (hypothermia, catalepsy and spontaneous activity) on
PD30, PD44, PD68, and PD114. These test points correspond to animal models of early
adolescence, late adolescence, early adulthood and full maturity, respectively.
In order to obtain a full dose-effect curve in each rat, 9-THC was administered in
a cumulative dosing procedure (0, 3, 10, 30 and 100 mg/kg) on each of these days (Table
1). The cumulative dosing sessions began with the determination of body weight and
baseline body temperature followed by an intraperitoneal injection of vehicle.
Temperature was measured by inserting a rectal thermometer probe 40 mm (adolescents)
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or 45 mm (adults) into the rectum. The probe was dipped in mineral oil maintained at
37oC for lubrication before insertion into the rectum. The rats were then returned to their
home cages for 20 minutes. When 20 minutes had elapsed, the rats were placed in a
locomotion chamber for 5 minutes.

Table 1
Cumulative dosing matrix
Time (mins)
-5
0
20
25
30
35
55
60
65
70
90
95
100
105
125
130
135
140
160
165
170

Procedure
Baseline Body Temperature
Vehicle Injection
Locomotion
Body Temperature
Time on Bar Apparatus
3 mg/kg THC Injection
Locomotion
Body Temperature
Time on Bar Apparatus
7 mg/kg THC Injection
Locomotion
Body Temperature
Time on Bar Apparatus
20 mg/kg THC Injection
Locomotion
Body Temperature
Time on Bar Apparatus
70 mg/kg THC Injection
Locomotion
Body Temperature
Time on Bar Apparatus

During the locomotion session, measures of fine movement (i.e., breaking a single
beam that lies adjacent to the rat’s position) and ambulatory movement (i.e., breaking two
or more beams as the rat moves across the chamber floor) were recorded. The software
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that recorded movement in the chamber automatically discounted rapid, successive
interruptions of the same beam because these types of data are indicative of stereotypic
behavior and were not included in the measure of gross locomotion. The system also
quantified movement along the periphery of the chamber as well as movement near the
center of the chamber.
At the end of the locomotion session, body temperature was measured again and
then the rats were immediately placed on the bar apparatus for up to 5 minutes. During
the 5-minute bar apparatus session, the total amount of time (in seconds) that the front
paws of a rat remained in contact with the bar was recorded. If both of the paws dropped
from the bar, the animal was repositioned as before. The session timer was stopped
briefly while the animal was repositioned. If the rat voluntarily removed both paws from
the bar 10 times during the session, the session was be stopped, and amount of time spent
with both paws on the bar was recorded as “zero”. Each rat was tested in all three of these
procedures. The total amount of time required for these measures was no more than 15
minutes (i.e., 5 minutes in the locomotion chamber plus 5 minutes on the bar apparatus
plus time required for measurement of body temperature).
Immediately after the end of the bar apparatus session, the rats were injected
intraperitoneally with a 3 mg/kg dose of 9-THC and returned to their home cage. When
20 minutes had elapsed, the entire triad of measures was repeated. These measures were
taken 3 more times after the rats have received successive intraperitoneal injections of 7
mg/kg, 20 mg/kg and 70 mg/kg 9-THC. By using this method, a full dose-effect curve
(0-100 mg/kg 9-THC) was generated for all of the rats at each age point.
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On postnatal day 128, 9-THC-induced antinociception was measured with a
radiant-heat, tail-flick analgesia meter (Model #1430, Columbus Instruments, Columbus,
OH). The animals were weighed and injected intraperitoneally with vehicle (92.2%
saline, 7.8% Tween 80) and returned to their home cage. After 30 minutes, latency to
flick their tail away from the heat source was measured. Immediately after this baseline
response was recorded, the animals were injected intraperitoneally with 9-THC (30
mg/kg) and again returned to their home cage. After another 30 minutes had elapsed, a
second tail-flick measurement was taken.
Subsequently, experiments were conducted to examine how 9-THC affected
food intake. In order to avoid carry-over effects, the first of the feeding trials was
conducted fourteen days after the antinociception session (postnatal day 142). The rats
were allowed ad libitum access to their normal food and water until they were weighed
and injected intraperitoneally with 9-THC. These studies will be conducted under freefeeding conditions because the high feeding rates that are commonly seen in fooddeprived rats can obscure drug effects (Williams and Kirkham, 2002).
Once initiated, feeding trials were conducted every 7 days until all doses of 9THC (0, 0.3, 1, 3, 10 and 30 mg/kg) were tested. The various doses of 9-THC were
delivered a randomized order (modified Latin squares) so that drug dose did not vary
systematically with age. After treatment with 9-THC, the rats were returned to their
home cage for 30 minutes. All of the food was removed from the home cage at this time.
After the 30-minute pretreatment time had elapsed, a pre-weighed portion of the normal
food (i.e., standard chow for rats on the control diet and high-fat chow for rats on the
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high-fat diet) was placed in the home cage. After 1 hour, the food portion was removed,
weighed and immediately returned to the cage. This procedure was repeated after another
hour had elapsed. The food portion was removed and weighed again after 3 hours had
elapsed and the total mass of food consumed during the feeding trial was recorded.
Males. A group of male Long-Evans rats (n = 9), was fed a high-fat diet (4.63
kcal/g; 33% of calories from fat) beginning at postnatal day 30 (PD30). A separate group
of male Long-Evans rats (n = 9) was fed a control diet (3.75 kcal/g; 17% of calories from
fat) for the duration of these experiments. For male rats, cannabinoid activity was
assessed in a triad of measures (hypothermia, catalepsy and spontaneous activity) on
PD30, PD37, PD44, PD61, PD68, and PD114. The procedure utilized at each of these age
points was identical to the procedure for the described for the female rats. By using this
method, a full dose-effect curve (0-100 mg/kg 9-THC) was generated for all of the rats
at each age point.
Subsequently, experiments were conducted to examine how 9-THC affected
food intake. In order to avoid carry-over effects, the first of the feeding trials was
conducted fourteen days after the last cumulative dosing session (postnatal day 128).
These feeding trials were conducted under both free-fed conditions and after 24 hours of
food deprivation. Once initiated, feeding trials were conducted every 7 days until all
doses of 9-THC (0, 0.3, 1, 3, and 10 mg/kg) were tested under each condition. The
nutritional status of the rats (food-deprived vs. free-fed) and the various doses of 9-THC
were delivered a randomized order so that neither condition nor drug dose varied
systematically with age.
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After treatment with 9-THC, the rats were returned to their home cage for 30
minutes. All of the food was removed from the home cage at this time. After the 30minute pretreatment time had elapsed, a pre-weighed portion of the normal food (i.e.,
standard chow for rats on the control diet and high-fat chow for rats on the high-fat diet)
was placed in the home cage. After 1 hour, the pre-weighed portion of food was removed,
weighed and the total mass of food consumed during the feeding trial was recorded.
When the male rats were aged 19 months, 9-THC-induced antinociception was
measured with a radiant-heat, tail-flick analgesia meter (Model #1430, Columbus
Instruments, Columbus, OH). The procedure for measuring the antinociceptive properties
of 9-THC in male rats was the same as the above-described procedure that was used
with the female rats.
Two separate groups of male rats (n = 4) were used to explore the possibility that
context-specific (or behavioral) tolerance affected the repeated measures that are intrinsic
to this experimental design (Table 1). For each group, 9-THC-induced hypothermia was
measured in a cumulative dosing procedure (0-100 mg/kg) on postnatal day 30 and again
on postnatal day 37. For the first group, both of these experiments was conducted in an
identical environment (e.g., the same behavioral pharmacology lab). For the second
group of rats, the two experiments were conducted in two disparate environments (e.g., a
behavioral pharmacology lab and in the vivarium).
Data Analysis
Sample size for each experiment was determined with SigmaStat (ver. 3.5; Systat
Software Corporation, Point Richmond, CA). Parameters entered in this program
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included effect size, standard deviation, number of groups, desired power, and alpha
level. Values for the proposed studies, a small-to-medium effect size (0.15; Cohen et al.,

Table 2
Methodology for Examining Context-specific Tolerance
Location of 1st Test

Location of 2nd test

Group 1

Behavioral
Pharmacology Lab

Behavioral
Pharmacology Lab

Group 2

Behavioral
Pharmacology Lab

Vivarium

2003) was chosen for the power analysis. Based on standard deviations derived from
probe trials, the standard deviation for these calculations will be estimated at 0.125. By
convention, the desired power level will be set at 0.80 and the alpha level will be set at
0.05 (Howell, 1997).
SigmaStat calculated that a sample size of 9 per group was necessary in order to
detect differences based on these parameters. This sample size was consistent with sizes
used by this lab previously in similar studies and was used for all studies in this protocol.
In total, 44 animals were required to complete these studies. These studies commenced
on postnatal day 30 for both male and female rats and and concluded on postnatal day
190 for female rats and on or about postnatal day 578 for male rats.
All statistical analyses, except ED50 calculations, were conducted using SigmaStat
statistical software. GraphPad Prism was used to determine ED50 values and 95%
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confidence limits as necessary. Growth rates were compared by linear regression
analysis. Bodyweights, average daily food consumption, hypothermia, locomotor
activity, time with paws on bar apparatus, tail-flick latencies and food-intake were
analyzed with a split-plot ANOVA. The development of context-specific tolerance was
analyzed with a two-factor (dose, location of second test), repeated measures ANOVA.
Changes in tail-flick latency were be analyzed with a one-factor (diet) ANOVA. Tukey
post hoc tests ( = 0.05) will be used to specify differences revealed by significant
ANOVAs. The diet-related changes in potency of 9-THC(ED50 values and 95%
confidence limits) were determined by fitting a non-linear regression equation against the
corresponding dose-effect curve. Each measurement was plotted against the common
logarithm of the dose. In order to determine the ED50 values for 9-THC, the amount of
time with paws on bar apparatus was expressed as a percentage of the total session length
(300 seconds). Similarly, locomotor activity at various doses of 9-THC was expressed
as a percentage of baseline locomotor activity.
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Results

Effects of a High-fat Diet on Bodyweight
Females. As expected, female rats gained a significant amount of weight over the
course of development [main effect of postnatal day, F(26, 416) = 301.204, p < 0.001].
Further, female rats fed a high fat diet overall weighed significantly more than those fed a
control diet [main effect of diet, F(1, 16) = 37.483, p < 0.001], (Fig. 2). A significant
interaction between diet and postnatal day on bodyweights was not detected, F(26, 416) =
0.9136, p < 0.590.
Males. Male rats also exhibited a significant main effect of diet on bodyweight,
F(1, 15) = 126.804, p < 0.001, with those fed a high fat diet being heavier, as well as a
significant main effect of postnatal day on bodyweight, F(26, 390) = 671.428, p < 0.001
(Fig. 3). No significant interaction between diet and postnatal day on bodyweight was
detected, F(26, 390) = 0.7885, p = 0.7631.
Psychomotor Effects – Time on Bar Apparatus
Females. Baseline measurements of the amount of time female rats spent on the
bar apparatus were conducted on postnatal day 30. At baseline, there was a significant
main effect of 9-THC on the amount of time spent on the bar apparatus, F(4, 64) =
85.164, p < 0.001 (Fig. 4). When tested on postnatal day 30, both groups of rats spent
significantly more time on the bar apparatus when treated with 10 mg/kg, 30 mg /kg and
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Figure 2. Growth chart for female rats. Despite the presence of significant main
effects of diet and postnatal day on bodyweight, no significant interactions of diet and
postnatal day on bodyweight were detected.
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Figure 3. Growth chart for male rats. Despite the presence of significant main effects
of diet and postnatal day on bodyweight, no significant interactions of diet and
postnatal day on bodyweight were detected.
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100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for all measures).
In contrast, a 3 mg/kg dose of 9-THC did not significantly increase the amount of time
the rats spent on the bar apparatus. However, there was no significant main effect of diet
on the amount of time spent on bar apparatus, F(1, 16) = 0.593, p = 0.452 and no
significant interaction between diet and dose of 9-THC was detected, F(4, 64) = 0.606,
p = 0.659.
The results for the amount of time female rats spent on the bar apparatus at
postnatal day 44 were similar to the results observed on postnatal day 30. At postnatal
day 44, there was again a significant main effect of 9-THC on the amount of time spent
on the bar apparatus, F(4, 64) = 123.167, p < 0.001 (Fig. 5). Both groups of rats spent
significantly more time on the bar apparatus when treated with 10 mg/kg, 30 mg/kg and
100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for all measures).
Again, a 3 mg/kg dose of 9-THC did not significantly increase the amount of time the
rats spent on the bar apparatus when tested at postnatal day 44. There was no main effect
of diet on the amount of time spent on bar apparatus, F(1,16) = 2.806, p = 0.113) and no
significant interaction between diet and dose of 9-THC was detected, F(4, 64) = 1.384,
(p = 0.250).
By postnatal day 68, however, significant diet-related differences in the amount of
time spent on the bar apparatus became apparent (Fig. 6). Analyses revealed a significant
interaction between the type of diet consumed and the dose of 9-THC administered, F(4,
64) = 2.685, p = 0.039. At this age point, the amount of time that female rats spent with
their paws on the bar apparatus after treatment with 9-THC was dependent upon which
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Figure 4. Time on bar apparatus for female rats at PD30. Expressed as percentage of
the total session time (mean +/- SEM) that female rats remained on the bar apparatus
at postnatal day 30. While 9-THC produced a significant, dose-dependent increase in
time on the bar apparatus, the groups exhibited indistinguishable drug responses. Data
points highlighted with an “#” are significantly different from the respective vehicletreated conditions.
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Figure 5. Time on bar apparatus for female rats at PD44. Expressed as percentage of
the total session time (mean +/- SEM) that female rats remained on the bar apparatus
at postnatal day 44. While 9-THC continued to produce a significant, dosedependent increase in time on the bar apparatus, no between group differences were
noted. Data points highlighted with a “#” are significantly different from the
respective vehicle-treated conditions.
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Figure 6. Time on bar apparatus for female rats at PD68. Expressed as a percentage
of the total session time (mean +/- SEM) that female rats remained on the bar
apparatus at postnatal day 68. A significant interaction between 9-THC and the
type of diet consumed was evident. Though 9-THC continued to produce a
significant, dose-dependent increase in time on the bar apparatus for both groups,
the female rats maintained on a high-fat diet spent significantly less time on the bar
apparatus than the female rats maintained on the control diet when treated with 30
mg/kg and 100 mg/kg doses of 9-THC. Data points highlighted with “#” are
significantly different from the respective vehicle-treated conditions. Data points
highlighted with asterisk are significantly different from each other. (“*” indicates
p < 0.05; “**” indicates p < 0.01.)
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diet they consumed. Although 9-THC produced a dose-dependent increase in the
amount of time spent on the bar apparatus in both groups, the rats that were maintained
on a high-fat diet spent significantly less time on the bar apparatus than did the rats
maintained on the control diet when treated with 30 mg/kg and 100 mg/kg doses of 9THC (p < 0.05 for both measures). Despite these differences in the amount of time spent
on the bar apparatus at postnatal day 68, the 95% confidence intervals for the ED50 values
of 9-THC overlapped (Table 3), indicating the absence of diet-related differences in the
potency of 9-THC.
Table 3
Potency of 9-THC in female rats.
Females
HFD

Bar
Apparatus

Locomotor
Activity

Bar
Apparatus

Locomotor
Activity

PD30
Control

HFD

PD44
Control

ED50
(mg/kg)

12

15.7

12.9

10.3

95% CI
(mg/kg)

10.713.4

13.418.4

11.514.4

8.113.0

ED50
(mg/kg)

147.8

46.3

n/a

2499

19.517.01121
126.6
PD68

n/a

95% CI
(mg/kg)

n/a
PD114

HFD

Control

HFD

Control

ED50
(mg/kg)

11.5

6.9

25.1

5.2

95% CI
(mg/kg)

8.814.9

4.9-9.7

20.630.6

3.5-7.7

ED50
(mg/kg)

38

29.4

9.4

9.4

95% CI
(mg/kg)

27.153.2

1.9466.2

5.117.2

5.117.2
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When tested on postnatal day 114, the diet-related differences in the amount of
time spent on the bar apparatus were again obvious (Fig. 7). Analyses revealed a
significant interaction between the type of diet consumed and the dose of 9-THC
on the amount of time spent with forepaws on the bar apparatus, F(4, 64) = 6.875, p <
0.001. Again, 9-THC produced a dose-dependent increase in the amount of time spent
on the bar apparatus in both groups. Rats maintained on a high-fat diet spent significantly
less time on the bar apparatus than did the rats maintained on the control diet when
treated with 10 mg/kg 9-THC and 30 mg/kg 9-THC (p < 0.05 for both measures). On
postnatal 114, the 95% confidence intervals for the ED50 values of 9-THC did not
overlap (Table 3). At this age point, 9-THC was significantly less potent in the rats
maintained on a high-fat diet than in the rats maintained on a control diet.
Even though there were significant inter-group differences in the amount of time
spent on the bar apparatus after postnatal day 68, other non-systematic observations
suggest that the measurements used in these experiments may underestimate the
differences between the groups (Fig. 8). At doses of 9-THC above 10 mg/kg, the female
rats fed the control diet typically moved their heads and forepaws very little and appeared
quite sedated while on the bar apparatus. At those same doses, the female rats fed a highfat diet typically moved their heads, usually changed their posture at least once during the
course of the 5-minute session on the bar apparatus and frequently re-positioned their
paws or moved along the bar apparatus. At doses of 9-THC above 30 mg/kg, female rats
fed a high-fat diet commonly engaged in a series of repetitive head
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Figure 7. Time on bar apparatus for female rats at PD114. Percentage of the total
session time (mean +/- SEM) that female rats remained on the bar apparatus at
postnatal day 114. A significant interaction between 9-THC and the type of diet
consumed was evident. Though 9-THC continued to produce a significant, dosedependent increase in time on the bar apparatus for both groups, the female rats
maintained on a high-fat diet spent significantly less time on the bar apparatus than the
female rats maintained on the control diet when treated with 10 mg/kg and 30 mg/kg
doses of 9-THC. Data points highlighted with “#” are significantly different from the
respective vehicle-treated conditions. Data points highlighted with asterisk are
significantly different from each other. (“*” indicates p < 0.05; “***” indicates p <
0.001.)
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Figure 8. Differences in activity during bar apparatus sessions. Non-systematic
observations suggest that the female rats maintained on a high-fat diet were
significantly less affected by moderate and high doses of 9-THC than were female
rats maintained on the control diet. These photos were taken after the rats had been
treated with a 10 mg/kg dose of 9-THC. The female rat maintained on a high-fat diet
(right) frequently exhibited overt head movements, shifts in posture and lateral
movements along the bar apparatus. The female rat maintained on the control diet
(left) was virtually immobile. These differences in activity were not captured by the
operational definition the dependent variable because the front paws rarely the left bar
apparatus while the rat maintained on a high-fat diet executed these movements.
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movements. These movements were typically from side-to-side and were occasionally
accompanied by a slight shift in posture or body position.
In general, there were no differences between the groups in the amount of time
spent on the bar apparatus until the female rats reached early adulthood (postnatal day
68). After postnatal day 68, the female rats maintained on the high-fat diet were
significantly less sensitive to 9-THC-induced increases in the amount of time spent on
the bar apparatus.
Males. Like the female rats, baseline measures of time spent on the bar apparatus
for the male rats were taken on postnatal day 30. At baseline, there was a significant main
effect of 9-THC on the amount of time spent on the bar apparatus, F(4, 64) = 115.781, p
< 0.001 (Fig. 9). Both groups of male rats spent significantly more time on the bar
apparatus when treated with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC than
when treated with vehicle (p < 0.05 for all measures). A 3 mg/kg dose of 9-THC,
however, did not significantly increase the amount of time the male rats spent on the bar
apparatus. There was no main effect of diet on the amount of time spent on bar apparatus,
F(1, 16) = 0.0534, p = 0.820 and no significant interaction between diet and dose was
detected, F(4, 64) = 0.0137, p = 1.000.
When the male rats were tested at postnatal day 37, the significant main effect of
9-THC on the amount of time spent on the bar apparatus persisted, F(4, 60) = 50.829, p
< 0.001 (Fig. 10). Male rats maintained on the control diet spent significantly more time
on the bar apparatus when treated with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9THC than when treated with vehicle (p < 0.05 for all measures). Male rats maintained on

44

Males - PD30
Control Diet
100%

High-fat Diet

Time on Bar Apparatus(% of Session)

#

#

#

75%

#

50%

#

25%

#

0%
VEH

3

10

30

100

 9-THC (mg/kg)

Figure 9. Time on bar apparatus for male rats at PD30. Percent of the total session
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 30.
Though 9-THC to produce a significant, dose-dependent increase in time on the bar
apparatus, the groups were again indistinguishable in terms of their responses. Data
points highlighted with a “#” are significantly different from the respective vehicletreated conditions.
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a high-fat diet spent significantly more time on the bar apparatus when treated with 30
mg/kg and 100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for both
measures). A 3 mg/kg dose of 9-THC did not significantly increase the amount of time
the rats spent on the bar apparatus for either group. At postnatal day 37, like at postnatal
day 30, there was no main effect of diet on the amount of time spent on bar apparatus
F(1, 15) = 0.203, p = 0.659) and no significant interaction between diet and dose was
detected, F(4, 60) = 0.419, p = 0.795.
When the male rats were tested at postnatal day 44, there was again a significant
main effect of 9-THC on the amount of time spent on the bar apparatus, F(4, 60) =
30.387, p < 0.001 (Fig. 12). Male rats maintained on the control diet spent significantly
more time on the bar apparatus when treated with 30 mg/kg and 100 mg/kg doses of 9THC than when treated with vehicle (p < 0.05 for both measures). Like previous tests, a 3
mg/kg dose of 9-THC failed to significantly increase the amount of time the rats spent
on the bar apparatus. Also like previous tests with male rats, there was no main effect of
diet on the amount of time spent on bar apparatus F(1, 15) = 0.00198, p = 0.965) and no
significant interaction between diet and dose was detected, F(4, 60) = 1.316, p = 0.275.
When the male rats were tested at postnatal day 61, the significant main effect of
9-THC on the amount of time spent on the bar apparatus was still apparent, F(4, 60) =
36.510, p < 0.001 (Fig. 13). Both groups of male rats diet spent significantly more time
on the bar apparatus when treated with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9THC than when treated with vehicle (p < 0.05 for all measures). A 3 mg/kg dose of 9THC did not significantly increase the amount of time the rats spent on the bar apparatus
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Figure 10. Time on bar apparatus for male rats at PD37. Percent of the total session
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 37.
Just as at PD30, 9-THC produced a significant, dose-dependent increase in time on
the bar apparatus, but the responses between the groups were again indistinguishable.
Data points highlighted with a “#” are significantly different from the respective
vehicle-treated conditions.
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Figure 11. Time on bar apparatus for male rats at PD44. Percent of the total session
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 44.
While 9-THC continued to produce a significant, dose-dependent increase in time on
the bar apparatus, the responses between the groups were again indistinguishable. Data
points highlighted with an “#” are significantly different from the respective vehicletreated conditions.
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for either group. At postnatal day 61, there was no main effect of diet on the amount of
time spent on bar apparatus F(1, 15) = 0.599, p = 0.451) and no significant interaction
between diet and dose was detected, F(4, 60) = 0.555, p = 0.696.
For the male rats, the previously noted trends in the amount of time spent on the
bar apparatus continued on postnatal day 68 (Fig. 13). At this age point, male rats
displayed a significant main effect of 9-THC on the amount of time spent on the bar
apparatus, F(4, 60) = 39.519, p < 0.001. Like the previous tests, both groups of male rats
spent significantly more time on the bar apparatus when treated with 10 mg/kg, 30 mg/kg
and 100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for all
measures) and a 3 mg/kg dose of 9-THC did not increase the amount of time the rats
spent on the bar apparatus significantly. There were again no main effect of diet on the
amount of time spent on bar apparatus F(1, 15) = 0.0176, p = 0.896 and no significant
interaction between diet and dose was detected, F(4, 60) = 0.578, p = 0.680.
When the male rats were tested on postnatal day 114, however, significant dietrelated differences in the amount of time spent on the bar apparatus were evident (Fig.
14). At this age point, there was a significant interaction between the type of diet
consumed and the dose of 9-THC administered, F(4, 60) = 8.230, p < 0.001, with 9THC producing a significant dose-dependent increase in the amount of time spent on the
bar apparatus in both groups. Male rats maintained on a high-fat diet spent significantly
less time on the bar apparatus than did the rats maintained on the control diet when
treated with 10 mg/kg 9-THC (p < 0.05). On postnatal 114, 9-THC also appeared to be
significantly less potent in the male rats maintained on a high-fat diet than in the male
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Figure 12. Time on bar apparatus for male rats at PD61. Percent of the total session
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 61.
While 9-THC continued to produce a significant, dose-dependent increase in time on
the bar apparatus, the responses between the groups were again indistinguishable. Data
points highlighted with a “#” are significantly different from the respective vehicletreated conditions.
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Figure 13. Time on bar apparatus for male rats at PD68. Percent of the total session
time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal day 68.
While 9-THC continued to produce a significant, dose-dependent increase in time on
the bar apparatus, the responses between the groups were again indistinguishable. Data
points highlighted with a “#” are significantly different from the respective vehicletreated conditions.
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Figure 14. Time on bar apparatus for male rats at PD114. Percentage of the total
session time (mean +/- SEM) that male rats remained on the bar apparatus at postnatal
day 114. A significant interaction between 9-THC and the type of diet consumed
was evident. Though 9-THC continued to produce a significant, dose-dependent
increase in time on the bar apparatus for both groups, the male rats maintained on a
high-fat diet spent significantly less time on the bar apparatus than the male rats
maintained on the control diet when treated with a 10 mg/kg dose of 9-THC. Data
points highlighted with a “#” are significantly different from the respective vehicletreated conditions. Data points highlighted with asterisk are significantly different
from each other. (“***” indicates p < 0.001.)
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rats maintained on a control diet. The 95% confidence intervals for the ED50 values of 9THC did not overlap (Table 4).

Table 4
Potency of 9-THC in male rats.
PD30

Males

Bar
ED50
Apparatus (mg/kg)

PD37

PD44

HFD

Control

HFD

Control

HFD

Control

14.3

15.3

22.5

11.0

15.6

6.4

95% CL
11.8-17.3 12.8-18.4 19.1-26.5 9.3-13.1 12.3-19.9
(mg/kg)
Locomotor ED50
Activity (mg/kg)
95% CL
(mg/kg)

6.2

12.5

n/a

n/a

n/a

n/a

4.3-9.1

8.6-18.3

n/a

n/a

n/a

n/a

PD61
HFD
Control
Bar
ED50
Apparatus (mg/kg)
95% CL
(mg/kg)
Locomotor ED50
Activity (mg/kg)
95% CL
(mg/kg)

4.5-9.2

5.8
4.2-8.0

8.0

PD68
HFD
Control

PD114
HFD
Control

14.3

7.3

39.3

5.3

5.7-9.4

27.2-56.8

3.4-8.3

5.2-12.2 12.2-16.9

6.6

22.0

n/a

38.0

n/a

28.9

5.3-8.2

13.9-34.8

n/a

27.1-53.2

n/a

22.5-37.1

Psychomotor Effects – Gross Locomotor Activity
Females. Baseline measures for gross locomotor activity in female rats were taken
on postnatal day 30. At baseline, there was a significant main effect of 9-THC on the
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number of beams broken during locomotor testing session, F(4, 64) = 23.764, p < 0.001
(Fig. 15). Both groups of female rats broke fewer beams when treated with 30 mg/kg and
100 mg/kg doses of 9-THC than when treated with vehicle (p < 0.05 for both measures).
A 3 mg/kg dose of 9-THC did not significantly affect the number of beams broken
during the session. There was no main effect of diet on the number of beams broken F(1,
16) = 0.0110, p = 0.918, and no significant interaction between the type of diet and the
dose of 9-THC on the number of beams broken was detected F(4, 64) = 0.434, p =
0.783.
At postnatal day 44, the significant main effect of 9-THC on the number of
beams broken persisted, F(4, 64) = 14.058, p < 0.001 (Fig. 16). Female rats broke
significantly fewer beams when treated with a 100 mg/kg dose of 9-THC. There was no
main effect of diet on the number of beams broken F(1, 16) = 1.910, p = 0.186 and no
significant interaction between the type of diet and the dose of 9-THC on the number of
beams broken was detected F(4, 64) = 1.043, p = 0.392.
By postnatal day 68, a significant interaction between the type of diet consumed
and the dose of 9-THC on the number of beams broken was evident, F(4, 64) = 4.188,
p = 0.004 (Fig. 17). At this age, female rats maintained on a high-fat diet broke a
significantly greater number of beams than did female rats maintained on a control diet
when each group was treated with a 30 mg/kg and a 100 mg /kg dose of 9-THC (p <
0.05 for both measures). For the females maintained on the control diet, the 95%
confidence intervals for ED50 values of 9-THC were 27.1 to 53.2 mg/kg (Table 3). In
contrast, it was not possible to calculate ED50 values under this dosing regimen for the
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Figure 15. Locomotor activity for female rats at PD30. Number of beams broken
(mean +/- SEM) by female rats after treatment with 9-THC on postnatal day 30.
Delta-9-THC dose-dependently decreased locomotor activity in both groups. No
between-group differences in drug response were detected. Data points highlighted
with a “#” are significantly different from the respective vehicle-treated conditions.
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Figure 16. Locomotor activity for female rats at PD44. Number of beams broken
(mean +/- SEM) by female rats after treatment with 9-THC on postnatal day 44.
Again, 9-THC dose-dependently decreased locomotor activity in both groups. No
between-group differences in drug response were detected. Data points highlighted
with a “#” are significantly different from the respective vehicle-treated conditions.
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Figure 17. Locomotor activity for female rats at PD68. Number of beams broken
(mean +/- SEM) by female rats after treatment with 9-THC at postnatal day 68. A
significant interaction between 9-THC and diet on the number of beams broken was
evident. Female rats maintained on the control diet broke significantly fewer beams
than female rats maintained on a high-fat diet when treated with 30 mg/kg and 100
mg/kg doses of 9-THC. Additionally, female rats maintained on the control diet
broke significantly fewer beams when treated with a 100 mg/kg dose of 9-THC than
when treated with vehicle. In contrast, the number of beams broken by female rats
maintained on a high-fat diet never varied significantly from the number broken under
vehicle conditions, regardless of the dose of 9-THC. Data points highlighted with “#”
are significantly different from the respective vehicle-treated conditions. Data points
highlighted with asterisk are significantly different from each other. (“*” indicates p <
0.05; “**” indicates p < 0.01.)
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female rats maintained on a high-fat diet because the relationship between the dose of 9THC and locomotor activity was non-linear.
The significant interaction between the type of diet consumed and the dose of 9THC on the number of beams broken continued at postnatal day 114, F(4, 64) = 3.292,
p = 0.016 (Fig. 18). At doses of 3 mg/kg, 10 mg/kg and a 100 mg /kg of 9-THC, female
rats maintained on a high-fat diet broke a significantly greater number of beams than did
female rats maintained on a control diet (p < 0.05 for all measures). Despite this
difference, the 95% confidence intervals for ED50 values of 9-THC overlapped (Table 3)
Males. Like females, baseline measures for gross locomotor activity in male rats
were taken on postnatal day 30. At baseline, there was a significant main effect of 9THC on the number of beams broken during a five-minute testing session, F(4, 64) =
1.894, p < 0.001 (Fig. 19). Both groups of male rats broke fewer beams when treated with
10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC than when treated with vehicle (p <
0.05 for all measures). A dose of 3 mg/kg 9-THC did not significantly affect the number
of beams broken during the session. At this age point, there was no main effect of diet on
the number of beams broken, F(1, 16) = 0.000484, p = 0.983, and no significant
interaction between the type of diet and the dose of 9-THC was detected, F(4, 64) =
1.894, p = 0.122.
At postnatal day 37, changes in gross locomotor activity in male rats after
treatment with 9-THC were similar to what was seen on postnatal day 30. There was a
significant main effect of 9-THC the number of beams broken, F(4, 60) = 8.089, p <
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Figure 18. Locomotor activity for female rats at PD114. Number of beams broken
(mean +/- SEM) by female rats after treatment with 9-THC at postnatal day 114. A
significant interaction between 9-THC and diet on the number of beams broken was
evident. Female rats maintained on the control diet broke significantly fewer beams
than female rats maintained on a high-fat diet when treated with 3 mg/kg, 10 mg/kg
and 100 mg/kg doses of 9-THC. Female rats maintained on the control diet broke
significantly fewer beams when treated with a 30 mg/kg and 100 mg/kg doses of 9THC than when treated with vehicle. Additionally, female rats maintained on a highfat diet broke a significantly larger number of beams when treated with a 3 mg/kg dose
of 9-THC than with treated with vehicle. Data points highlighted with “#” are
significantly different from the respective vehicle-treated conditions. Data points
highlighted with asterisk are significantly different from each other. (“*” indicates p <
0.05; “**” indicates p < 0.01.)

59

0.001 (Fig. 20) with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC reducing the
number of beams broken (p < 0.05). Analysis of the locomotor activity tests conducted
on male rats at postnatal day 37 failed to detect a significant main effect of diet the
number of beams broken, F(1, 15) = 0.0254, p = 0.876. Likewise, there was not a
significant interaction between type of diet consumed and the dose of 9-THC, F(4, 60) =
0.701, p = 0.595.
When tested on postnatal day 44, changes in gross locomotor activity after
treatment with 9-THC were similar to what was seen on postnatal day 37. There was a
significant main effect of 9-THC the number of beams broken, F(4, 60) = 6.131, p <
0.001 (Fig. 21) with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC reducing the
number of beams broken (p < 0.05). Analysis of the locomotor activity tests conducted
on male rats at postnatal day 44 failed to detect a significant main effect of diet the
number of beams broken, F(1, 15) = 0.828, p = 0.377. Likewise, there was not a
significant interaction between type of diet consumed and the dose of 9-THC, F(4, 60) =
0.327, p = 0.859.
At postnatal day 61, the significant main effect of 9-THC on the number of
beams broken during the locomotor sessions persisted, F(4, 60) = 19.865, p < 0.001 (Fig.
22) with 10 mg/kg, 30 mg/kg and 100 mg/kg doses of 9-THC reducing the number of
beams broken. No significant main effect of diet on the number of beams broken was
noted, F(1, 15) = 0.0851, p = 0.775, and the interaction between the type of diet and dose
of 9-THC was not significant, F(4, 60) = 1.137, p = 0.348.
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Figure 19. Locomotor activity for male rats at PD30. Number of beams broken (mean
+/- SEM) by male rats after treatment with 9-THC on postnatal day 30. Delta-9-THC
dose-dependently decreased locomotor activity in both groups. No between-group
differences in drug response were detected. Data points highlighted with a “#” are
significantly different from the respective vehicle-treated conditions.
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Figure 20. Locomotor activity for male rats at PD37. Number of beams broken (mean
+/- SEM) by male rats after treatment with 9-THC on postnatal day 37. A significant
main effect of 9-THC on the number of beams broken was noted, No between-group
differences in drug response were detected. Data points highlighted with a “#” are
significantly different from the respective vehicle-treated conditions.
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Figure 21. Locomotor activity for male rats at PD44. Number of beams broken (mean
+/- SEM) by male rats after treatment with 9-THC on postnatal day 44. A significant
main effect of 9-THC on the number of beams broken was noted, No between-group
differences in drug response were detected. Data points highlighted with a “#” are
significantly different from the respective vehicle-treated conditions.
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Figure 22. Locomotor activity for male rats at PD61. Number of beams broken (mean
+/- SEM) by male rats after treatment with 9-THC on postnatal day 61. A significant
main effect of 9-THC on the number of beams broken was noted, No between-group
differences in drug response were detected. Data points highlighted with a “#” are
significantly different from the respective vehicle-treated conditions.
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At postnatal day 68, there was still a significant main effect of 9-THC on the
number of beams broken during the locomotor sessions, F(4, 60) = 18.558, p < 0.001
(Fig. 23). Locomotor activity was inhibited significantly 30 mg/kg and 100 mg/kg doses
of 9-THC (p < 0.05 for both measures). No significant main effect of diet on the number
of beams broken was noted, F(1, 15) = 0.0380, p = 0.848, and the interaction between the
type of diet and dose of 9-THC was not significant, F(4,60) = 1.879, p = 0.126.
Similarly, at postnatal day 114, there was a significant main effect of 9-THC on
the number of beams broken during the locomotor sessions, F(4, 60) = 4.453, p = 0.003
(Fig. 24). However, 9-THC only inhibited locomotor activity significantly at a dose of
100 mg/kg (p < 0.05). Once again, no significant main effect of diet was noted, F(1, 15)
= 0.0995, p = 0.757, and the interaction between the dose of 9-THC and the type of diet
consumed was not significant, F(4, 60) = 1.541, p = 0.202.
Hypothermia
Females. Female rats exhibited a significant main effect of 9-THC on body
temperature each age point tested (Table 5). Doses of 9-THC that exceeded 30 mg/kg
commonly induced significant hypothermia when compared to vehicle treatment (p <
0.05). In contrast, neither a significant main effect of diet nor a significant interaction
between type of diet and 9-THC on hypothermia were noted for at any age point. In
female rats, the hypothermic effects of 9-THC were indistinguishable across the groups,
regardless of the age point when tested.
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Figure 23. Locomotor activity for male rats at PD68. Number of beams broken (mean
+/- SEM) by male rats after treatment with 9-THC on postnatal day 68. A significant
main effect of 9-THC on the number of beams broken was noted, No between-group
differences in drug response were detected. Data points highlighted with a “#” are
significantly different from the respective vehicle-treated conditions.
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Figure 24. Locomotor activity for male rats at PD114. Number of beams broken
(mean +/- SEM) by male rats after treatment with 9-THC on postnatal day 114. A
significant main effect of 9-THC on the number of beams broken was noted, No
between-group differences in drug response were detected. Data points highlighted
with a “#” are significantly different from the respective vehicle-treated conditions.
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Table 5
Effects of 9-THC and type of diet on body temperature.
Main Effect of 9-THC

Females

F-test

PD30
PD44
PD68
PD114

F(4,64)=143.99
F(4,64)=98.35
F(4,64)=64.57
F(4,64)=115.72

Males

F-test

PD30
PD37
PD44
PD61
PD68
PD114

F(4,64)=109.08
F(4,60)=12.98
F(4,60)=8.35
F(4,60)=15.22
F(4,60)=26.53
F(4,60)=26.46

pvalue
< 0.01
< 0.01
< 0.01
< 0.01
pvalue
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01
< 0.01

Main Effect of Diet

F-test
F(1,16)=1.42
F(1,16)=3.11
F(1,16)=0.22
F(1,16)=1.45
F-test
F(1,16)=0.85
F(1,15)=0.14
F(1,15)=0.05
F(1,15)=0.12
F(1,15)=0.39
F(1,15)=0.02

pvalue
> 0.05
> 0.05
> 0.05
> 0.05
pvalue
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05

Interaction of 9THC and Diet
F-test
F(4,64)=0.96
F(4,64)=1.77
F(4,64)=0.34
F(4,64)=0.41
F-test
F(4,64)=0.52
F(4,60)=1.24
F(4,60)=1.82
F(4,60)=0.38
F(4,60)=0.95
F(4,60)=0.17

pvalue
> 0.05
> 0.05
> 0.05
> 0.05
pvalue
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05
> 0.05

Males. For the male rats, there was also a significant main effect of 9-THC on
body temperature each age point tested (Table 5). Again, doses of 9-THC that exceeded
30 mg/kg induced significant hypothermia when compared to vehicle treatment (p <
0.05). Like the female rats, neither a significant main effect of diet nor a significant
interaction between type of diet and 9-THC on hypothermia were noted at any age point.
Again like the female rats, the hypothermic effects of 9-THC in male rats were
indistinguishable across the groups, regardless of the age point when tested. It is
noteworthy, however, that both groups of male rats exhibited an attenuated hypothermic
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response to 9-THC after the initial exposure and this pattern of diminished responses
persisted through postnatal day 114.
Antinociception – Tail-flick
Females. Female rats exhibited a significant interaction between 9-THC and diet
on latency to withdraw the tail from a radiant heat source, F(1, 16) = 9.075, p =0.008
(Fig. 25A). There was also a significant main effect of 9-THC on latency to withdraw
the tail from the source, F(1, 16) = 386.570, p < 0.001). In contrast, no main effect of diet
was detected, F(1, 16) = 0.0000684, p = 0.994. However, female rats maintained on a
high-fat diet exhibited a smaller drug-related change in latency to withdraw the tail from
the heat source (M = 3.636, SD = 0.603) than did the females maintained on the control
diet (M = 4.963, SD = 1.159), t(16) = 3.050, p = 0.008 (Fig. 25B).
Males. For male rats, there was a significant main effect of 9-THC on latency to
withdraw the tail from a radiant heat source, F(1, 15) = 427.949, p < 0.001 (Fig. 26A). A
30 mg/kg dose of 9-THC significantly increased latency to withdraw the tail from the
heat source than did treatment with vehicle (p < 0.05). There was not, however, a
significant main effect of the type of diet on tail withdrawal latency F(1, 15) = 0.0547, p
= 0.818. Additionally, no significant interaction between the type of diet and the dose of
9-THC was noted F(1, 15) = 0.418, p = 0.528. Unlike female rats, however, male rats
maintained on a high-fat diet exhibited a drug-related change in latency to withdraw the
tail from the heat source (M = 3.699, SD = 0.948) that was indistinguishable from the
drug-related change in latency exhibited by the males maintained on the control diet (M =
3.934, SD = 0.462), t(15) = 0.635, p = 0.535 (Fig. 26B).
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Figure 25. Antinociception in female rats. Changes in tail-flick latency produced by
treatment with 9-THC. Female rats demonstrated a significant interaction between
diet and 9-THC on tail-flick latencies (Fig 25A). A main effect of 9-THC on tailflick latency was also noted in female rats. Female rats maintained on a high-fat diet
also exhibited significantly smaller changes in tail-flick latencies after treatment with a
30 mg/kg dose of 9-THC than female rats maintained on the control diet (Fig. 25B;
“**” indicates p < 0.01).
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Figure 26. Antinociception in male rats. Changes in tail-flick latency produced by
treatment with 9-THC. Male rats demonstrated a significant main effect of 9-THC
on tail-flick latencies (Fig 26A). Unlike female rats, however, male rats did not exhibit
an interaction between diet and 9-THC on tail-flick latencies. Additionally, the
changes in tail-flick latencies induced by treatment with a 30 mg/kg dose of 9-THC
were indistinguishable across the groups (Fig. 26B).
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Food-intake
Females. During the first hour of a 3-hour feeding trial, female rats exhibited a
significant main effect of 9-THC on food intake, F(5, 80) = 6.855, p < 0.001 (Fig. 27).
Food intake increased significantly when rats were treated with 1 mg/kg, 3 mg/kg and 10
mg/kg doses of 9-THC when compared with vehicle. Analysis also revealed a
significant main effect of diet on food intake, F(1, 16) = 8.686, p = 0.009, with female
rats maintained on a high-fat diet consuming significantly more food during the feeding
trial than the female rats maintained on the control diet. Despite this, no interaction
between 9-THC and diet on food intake was detected, F(5, 80) = 0.809, p = 0.547.
Over the course of the full 3-hour feeding trial, female rats exhibited a significant
interaction of 9-THC and diet on food intake, F(5, 79) = 7.350, p < 0.001 (Fig. 28).
Analysis also revealed significant main effects of 9-THC dose, F(5, 79) = 9.915, p <
0.001, and of diet on food intake, F(1, 16) = 8.874, p = 0.009. The female rats maintained
on a high-fat diet ate significantly more than the female rats maintained on the control
diet when treated with 10 mg/kg and 30 mg /kg doses of 9-THC (p < 0.05 for both
measures). Conversely, female rats maintained on the control diet ate significantly more
than female rats maintained on a high-fat diet when treated with a 1 mg/kg dose of 9THC (p < 0.05).
In the same 3-hour experiment, female rats maintained on the control diet ate
significantly more when treated with a 1 mg/kg dose of 9-THC than with treated with
vehicle, p < 0.05. Female rats maintained on the high-fat diet, however, ate significantly
more when treated with 3 mg/kg and 10 mg/kg doses of 9-THC doses than when treated
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Figure 27. Relative food-intake over the first hour of a 3-hour feeding trial in female
rats. A significant main effect of 9-THC on food intake was noted. Neither an
interaction between diet and 9-THC on food intake nor a main effect of diet were
detected. Compared to vehicle conditions, food intake was stimulated 1 mg/kg – 10
mg/kg in female rats maintained on a high-fat diet. Female rats maintained on the
control diet ate significantly more when treated with a 1 mg/kg dose of 9-THC than
when treated with vehicle. Data points highlighted with “#” are significantly different
from the respective vehicle-treated conditions.
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Figure 28. Relative food-intake over the course of a 3-hour feeding trial in female
rats. A significant interaction between diet and 9-THC on food intake was noted.
Additionally, a main effect of dose and a main effect of diet were detected. Compared
to vehicle conditions, food intake was stimulated at 3 mg/kg and 10 mg/kg doses of
9-THC in female rats maintained on a high-fat diet. Female rats maintained on the
control diet ate significantly more when treated with a 1 mg/kg dose of 9-THC than
when treated with vehicle. Data points highlighted with “#” are significantly different
from the respective vehicle-treated conditions. Data points highlighted with an asterisk
are significantly different from the control diet group (“*” indicates p < 0.05; “***”
indicates p < 0.001).
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with vehicle (p < 0.05 for both measures). Both the smallest dose (e.g., 0.3 mg/kg) and
the largest dose of 9-THC (e.g., 30 mg/kg) failed to produce changes in food intake in
either group compared to vehicle.
Males. Over the course of a 1-hour feeding trial, the male rats exhibited a
significant interaction between diet and 9-THC on food intake, F(4,60) = 3.693, p =
0.009 (Fig. 29). Analysis also revealed significant main effects of 9-THC, F(4, 60) =
83.927, p < 0.001, and diet on food intake, F(1, 15) = 10.200, p = 0.006. Male rats
maintained on a high-fat diet ate significantly more than rats maintained on the control
diet when treated with vehicle and with a 3 mg/kg dose 9-THC (p < 0.05 for both
measures).
Context-specific tolerance
In a test of context-specific tolerance, male rats exhibited a significant interaction
between the drug exposure environment and 9-THC on hypothermia, F(4, 24) = 3.450, p
= 0.023. The male rats used in these experiments exhibited a main effect of 9-THC on
hypothermia when first exposed to the drug (PD30; Fig. 30A). Despite this, the rats that
were treated with 9-THC in two distinct environments (e.g., a behavioral pharmacology
lab and the vivarium) seven days apart (PD30 and PD37) exhibited significantly less
hypothermia on the second exposure than male rats that were treated with 9-THC in the
same environment at those same age points, p < 0.05 (Fig. 30B). At a 100 mg/kg dose,
the group of males that been exposed to 9-THC in two discrete locations exhibited less
hypothermia than the group of males that had been exposed to 9-THC in the same
environment twice (p < 0.05). The mean baseline body temperatures of the two groups
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were indistinguishable on PD30 (Lab/Lab group = 37.4oC, Lab/Vivarium group =
37.5oC) and on PD37 (Lab/Lab group = 37.6oC, Lab/Vivarium group = 37.3oC).
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Figure 29. Relative food-intake over the course of a 1-hour feeding trial in male rats.
A significant interaction between diet and 9-THC on food intake was noted.
Additionally, a main effect of dose and a main effect of diet were detected. Under
vehicle conditions, male rats maintained on a high-fat diet ate significantly more than
male rats maintained on the control diet. Compared to vehicle conditions, food intake
was inhibited at 3 mg/kg and 10 mg/kg doses of 9-THC in both groups of male rats.
Data points highlighted with “#” are significantly different from the respective
vehicle-treated conditions. Data points highlighted with an asterisk are significantly
different from the control diet group (“*” indicates p < 0.05; “***” indicates p < 0.001).
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Figure 30. Context-specific tolerance to the hypothermic properties of 9-THC. Upon
initial exposure (PD30; Fig. 30A), a significant main effect of 9-THC on
hypothermia was evident in both groups. The initial exposure to 9-THC took place in
a behavioral pharmacology lab for both groups. On the subsequent exposure (PD37;
Fig. 30B), a significant main effect of 9-THC on hypothermia was not detectable.
There was, however, a significant interaction between the location of the second
exposure and 9-THC on hypothermia. Data points highlighted with an asterisk are
significantly different from the control diet group (“*” p < 0.05).
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Discussion
Females
The most striking finding from these experiments is that, in female (but not male)
rats, consumption of a high-fat diet throughout adolescence resulted in reduced sensitivity
to the psychomotor effects of 9-THC. Within two weeks of the female rats being placed
on the high-fat diet, a trend suggestive of cross-tolerance to the psychomotor effects of
9-THC began to develop.
If present, this cross-tolerance may be the result of chronically elevated
endocannabinoid signaling produced by the inhibition of anandamide hydrolysis. The
type and quantity of polyunsaturated fatty acids in the diet can directly influence
endocannabinoid levels (Berger et al., 2001; Watanabe et al., 2003). Diets rich in omega6-polyunsaturated fatty acids may increase endocannabinoid levels by providing
additional substrate for FAAH (Matias et al., 2006). It may be possible to inhibit the
activity of by providing additional substrate because FAAH hydrolyzes the amide bond
of several common amines formed from long-chain fatty acids, including anandamide
(Schmid et al., 1985; Ueda et al., 1995).
By the time of the final assessment on postnatal day 114, 9-THC produced
smaller increases in the amount of time on the bar apparatus and did not inhibit
locomotion in females maintained on the high-fat diet compared to the females
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maintained on the control diet. Further, female rats maintained on this diet were less
sensitive to increased food intake caused by 9-THC. These changes in drug response are
strikingly similar to changes seen in rats that are tolerant to 9-THC (Fan et al., 1994).
The impression that female rats maintained on a high-fat diet became crosstolerant to the psychomotor effects of 9-THC was reinforced by other observations made
during these trials. Female rats maintained on a high-fat diet appeared to be less sedated
by moderate and high doses of 9-THC (i.e., above 10 mg/kg) than female rats
maintained on a control diet.
Other non-systematic observations made over the course of these experiments
suggest that female rats maintained on a high-fat diet found high doses of 9-THC (e.g.,
100 mg/kg) to be less aversive than female rats maintained on the control diet. Doses of
some drugs (i.e., naloxone, lithium chloride) that produce conditioned place aversion are
associated with an increase in ultrasonic vocalizations in the 20kHz frequency range as
compared to similar vocalizations made by vehicle-treated animals (Burgdorf et al.,
2001). Tones in the 20kHz range are near the high-end of the audible frequency range for
humans (Jauchem and Cook, 2007). When treated with a 100 mg/kg dose of 9-THC,
female rats maintained on the control diet commonly emitted sustained, high-pitched
vocalizations in response to being handled. In contrast, female rats maintained on a highfat diet rarely emitted vocal responses after being touched.
While suggestive of cross-tolerance to cannabinoids, however, the phenotype
resulting from this dietary regimen is distinct from that observed in cannabinoid tolerant
animals. For example, the female rats maintained on this diet also commonly exhibited a
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repetitive, stereotyped series head movements when treated with high doses of 9-THC,
an effect that does not occur in cannabinoid-tolerant rats. It is unclear whether these head
movements are a unique consequence of cannabinoid exposure after sustained
consumption of a high-fat diet or if they are simple exaggerations of other common
movements.
Notably, other cannabinoid-mediated effects, such as hypothermia and
antinociception were unaffected or minimally affected. Importantly, it has been
demonstrated that cannabinoid tolerance can develop in an asymmetric fashion. For
instance, after treatment with the CB1 agonist CP55, 940 for 4 consecutive days, rats
developed tolerance to the antinociceptive effects of the drug while the effect on operant
responding for food remained unchanged (DeVry et al., 2004). In this same study, a nonsignificant trend toward tolerance to the hypothermic effect of CP55, 940 was noted. In
addition, these data suggest that the observed changes in sensitivity to the psychomotor
effects of 9-THC in female rats maintained on a high-fat diet is probably not attributable
to differential metabolism or altered bioavailability of 9-THC.
It could be also reasoned that, because 9-THC is highly lipophilic and passes into
fat cells easily, changes in sensitivity to the psychomotor effects of 9-THC could be
attributable to increased adiposity and a concomitant reduction in drug bioavailability.
Once again, the lack of a main effect of diet on the hypothermic properties of 9-THC
argues against this conclusion.
Another interesting finding from these studies is related to observed changes in
food intake after treatment with 9-THC that occurred in female rats. The graphs of food
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intake after treatment with 9-THC depict a classical rightward shift in the dose-response
curve. As such, it appears that the female rats maintained on a high-fat diet were tolerant
to 9-THC-induced changes in food intake. The feeding behavior exhibited by the female
rats maintained on the control diet is consistent with 9-THC-induced changes reported
by other investigators (Williams et al., 1998). However, 9-THC continued to stimulate
food intake in the female rats that were maintained on a high-fat diet at doses that were
inactive or reduced food intake in other studies (Koch and Matthews, 2001).
It is important to point out a potential confound inherent to the food-intake
studies. Changes in food intake after treatment with 9-THC were measured using the
food that was normally consumed by each group. In other words, the female rats
maintained on a high-fat diet ate high-fat chow during the feeding trials. Similarly,
female rats maintained on the control diet ate standard rodent chow during their feeding
trials. Diets were not changed during the feeding trials because of potential inter-group
differences in the hedonic value of food or in the degree of neophobia. Though measuring
food intake with a common diet would have eliminated one condition that varied
systematically with drug treatment, it would have added at least one more.
It has been demonstrated that CP-55940, a potent CB1 agonist, differentially
enhances the reinforcing efficacy of corn oil as compared to vehicle (Ward and Dykstra,
2005), but it is not clear whether the high-fat diet used in these studies would be similarly
appealing after treatment with cannabinoids. It is possible that the observed inter-group
differences in food-intake are related to a differential influence of 9-THC on the intake
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of high-fat foods. An examination of the reinforcing efficacy of the high-fat diet used in
these studies provides one possible future direction for this project.
Males
In contrast, male rats maintained on a high-fat diet across the same developmental
interval were only affected to a moderate degree. Male rats maintained on a high-fat diet
spent more time on the bar apparatus when treated with 9-THC than male rats
maintained on the control diet, but this difference only appeared after the high-fat diet
had been consumed for 12 weeks and there were no overt differences in their level of
sedation at higher doses. Although this observation was not obtained systematically, it
stands in contrast to similar observations made during the trials with the female rats.
Additionally, male rats maintained on the control diet ate significantly less than male rats
maintained on a high-fat diet when treated with a 3 mg/kg dose of 9-THC, though
baseline differences in food intake between the groups complicate the interpretation of
these data. Measures of gross locomotion, hypothermia and antinociception did not reveal
any differences between the male rats maintained on a high-fat diet and male rats
maintained on the control diet.
Unlike female rats, the male rats maintained on a high-fat diet never differed
significantly from the male rats maintained on the control diet in terms of the number of
beams broken. Although a dose-dependent relationship between 9-THC dose and the
number of beams broken persisted through postnatal day 114, locomotion was only
significantly inhibited by large doses of 9-THC (e.g., 100 mg/kg) at that age. The
observation that both groups of male rats were less sensitive to the locomotor inhibition
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caused by 9-THC is intriguing, if not a bit puzzling. It is unlikely that these data can be
explained in terms of pharmacokinetic tolerance because these rats had not been treated
with 9-THC in 45 days. Pharmacokinetic explanations are also inconsistent with the
robust dose-dependent relationship between 9-THC and the amount of time spent on the
bar apparatus was apparent at postnatal day 114. This leaves open the possibility of
context-specific tolerance to the locomotor effects of 9-THC. Previous work has
demonstrated that behavioral tolerance to the locomotor effects of cannabinoids can be
produced after repeatedly pairing a cannabinoid agonist (HU210) with a locomotor
chamber (Hill et al., 2004). It is also possible that there are sex differences in the rate at
which these rats became habituated to the locomotor chamber (Bolivar et al., 2000).
Another intriguing finding from these experiments is the rapidity and degree to
which young male rats developed tolerance to the hypothermic effects of 9-THC. At
postnatal day 30, a 100 mg/kg dose of 9-THC administered under a cumulative dosing
regimen reduced body temperatures by about 2.1o Celsius. When the male rats were
tested again at postnatal day 37, 9-THC proved to be less efficacious at reducing body
temperature in both groups. Although a dose-dependent relationship between 9-THC
and hypothermia continued through postnatal day 114, the maximum degree of
hypothermia observed at any subsequent age point was about 1o Celsius. This trend held
true for both groups. Neither a main effect of diet nor an interaction of diet and dose of
9-THC on hypothermia were observed in male rats at any age.
When a separate group of young male rats were exposed to a cumulative dosing
protocol identical to the one used in these experiments, profound tolerance to the
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hypothermic effects of 9-THC developed after a single session. The tolerance that
developed after the cumulative dosing session on postnatal day 30 was still evident on
postnatal day 37 and was robust enough to eliminate the hypothermic response to even
large doses of 9-THC (100 mg/kg).
Even though there was no significant main effect of the dose 9-THC on
hypothermia at postnatal day 37, there was a significant interaction between the
environment where the second test was conducted and the hypothermic effects of 9THC. In a most unusual twist, however, hypothermic responses to 9-THC were least
evident in the environment that had never been paired 9-THC. At the very least, these
results suggest that context-specific tolerance plays a very small part in the diminished
hypothermic response that appeared after first cumulative dosing session.
Also unlike in the female rats, sustained consumption of a high-fat did not
significantly alter the antinociceptive properties of 9-THC in male rats. Under both
vehicle conditions and drug conditions, tail withdrawal latencies were virtually identical
for both groups. Likewise, both groups of male rats exhibited similar drug-related
changes in the latency to withdraw the tail from the noxious stimuli caused by the radiant
heat lamp.
Possible Mechanisms of Tolerance
While it cannot yet be concluded that the diet-related changes in sensitivity to the
effects of 9-THC observed in these studies involve receptor-level changes, there is no
evidence that observed differences in sensitivity to 9-THC are attributable to diet-related
differences in pharmacokinetics. The data, however, are generally consistent with the
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region-specific changes in CB1 receptor density reported in elsewhere (Harrold, et al.,
2002; Hayakawa, et al., 2007). In these studies, CB1 receptor expression appeared to
decline significantly in the striatum and nucleus accumbens while remaining essentially
unaltered in the hypothalamus after sustained consumption of a high-fat diet.
It would be expected that diminished CB1 receptor expression in the striatum
would result in reduced sensitivity to the psychomotor effects of 9-THC. Similarly, it
would be expected that diminished CB1 receptor expression in the nucleus accumbens
would attenuate the augmentation of the hedonic value of food caused by 9-THC. In
contrast, unaltered CB1 receptor expression in the hypothalamus would likely result in an
unaltered hypothermic response to 9-THC. Each of these expectations is consistent with
the data derived from these experiments.
Sex-differences in Drug Response
Despite the evidence that a high-fat diet alters sensitivity to 9-THC-induced
changes in food intake and, to a lesser degree, the antinociceptive properties of 9-THC,
these studies do not allow for a direct examination of sex differences because of differing
treatment histories for each sex. Male rats endured prolonged periods of inactivity (e.g.,
3-9 months) between testing in the triad of measures that compose the experimental core
of this project (e.g., hypothermia, gross locomotor activity, time on bar apparatus) and the
beginning of the feeding trials and the tail withdrawal tests. The female rats, on the other
hand, were moved from the triad of measures to the feeding trials and tail withdrawal
tests as rapidly as practical. Accordingly, the food intake data and the measures of
antinociception were conducted at different age points for each sex.
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It is well-known that nutritional status can affect the menstrual cycle of humans
(Frisch and McArthur, 1974). There is evidence of a positive correlation between the
consumption dietary fats and plasma estrogen levels during some phases of the human
menstrual cycle (Kaneda et al., 1997). Despite this, high dietary intake of polyunsaturated
fats is not associated with changes in menstrual cycle length (Nagata, Oba and Shimizu,
2006).
Given the evidence derived from humans, it is at least possible that high-fat diets
alter estrogen levels rodents. If present, such alterations could be important in the current
context because there is some evidence that CB1 receptor expression in the anterior
pituitary gland fluctuates during the course of the rodent estrous cycle and is related to
circulating levels of estrogen (Gonzalez et al., 2000). It is not clear, however, whether a
similar relationship exists in other brain areas. While it is possible that high-fat diets
modulate CB1 receptor expression in the brain by altering circulating estrogen levels,
there is scant evidence to support such a conclusion.
Recent evidence from experiments with ovariectomized mice, however, suggests
that progesterone may be an important modulator of cannabinoid-induced catalepsy
(Kalbasi Anaraki et al., 2008). Cannabinoid-induced catalepsy was unaltered when
ovariectomized mice were treated with estrogen, but treatment with progesterone
potentiated the cataleptogenic properties of cannabinoids. It is important to remember,
however, that progesterone levels may decline in female rats that consume high levels of
omega-6-polyunsaturated fats (Trujillo and Broughton, 1995). The corn oil used as a
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source of dietary fat in this study is rich in omega-6-polyunsaturated fats (U.S.
Department of Agriculture, Agricultural Research Service, 2005).
While there appears to be a relationship between the type of diet used in these
experiments and low levels of progesterone levels in rats, there is no direct evidence that
low levels of progesterone would attenuate catalepsy-like behavior induced by 9-THC.
The relationship between high-fat diets, progesterone levels and the cataleptogenic
properties 9-THC is one possible future direction for this project.
The experiments with the male rats were conducted in the summer and
experiments with the female rats were conducted nearly fifteen months later in the late
fall and early winter. As a consequence, potential seasonal differences in the data make a
direct comparison of sex-differences in diet-related changes in sensitivity to 9-THC
inadvisable. Despite this, there was an obvious disparity in the diet-related changes in the
sensitivity to 9-THC that were observed within each sex. In male rats, there were very
few diet-related changes in the psychomotor effects of 9-THC, regardless of the diet
consumed. As mentioned previously, however, female rats had been maintained on highfat diet for at least thirty-eight days were much less sensitive to the psychomotor effects
of 9-THC than female rats maintained on the control diet.
The results of these experiments raise questions regarding the relationship
between sustained consumption of a high-fat diet and the developing brain. It is not clear
whether diet-related differences in sensitivity to 9-THC are caused by the consumption
of high-fat diets during a vulnerable period of brain development, or whether rats that are
placed on high-fat diets in adulthood would eventually exhibit a similar type of
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desensitization. These are compelling questions and they may be related to an important
public health issue, but they cannot be answered without further experimentation.
Despite these limitations, the apparent sex differences in the effect of a high-fat
diet on sensitivity to some of the pharmacological effects of 9-THC are intriguing. As of
yet, the degree to which sex hormones influence these differences is unclear. Clearly,
parallel trials should be conducted with groups of overiectomized females and castrated
males maintained on each of the diets. It is also not yet clear whether the diet-related
differences in sensitivity to 9-THC involve differences in CB1 receptor sensitivity.
Accordingly, CB1 receptor function should be studied in drug-naïve rats of both sexes
that have been maintained on each of the diets.
The degree to which the various phases of the estrous cycle influence sensitivity
to 9-THC in rodents is of fundamental importance, but there is a paucity of research in
this area. The female rats used in these studies were housed separately in cages that were
under positive airflow. This housing arrangement and the positive airflow environment of
the home cages should have impaired estrous synchrony in these rats (Schank and
McClintock, 1997).
The experiments detailed here were designed as part of a developmental study and
employ methodologies that are distinct from those used in studies designed to explore
sex-differences. While the phase of the estrous cycle was not considered during these
experiments, it is improbable that the female rats maintained on a high-fat diet randomly
expressed synchronized estrous cycles while being uniformly out-of-phase with the
female rats maintained on the control diet. Female rats have an estrous cycle that lasts
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between 4 and 5 days (Butterstein et al., 1997). Assuming a mean estrous cycle duration
of 4.5 days, the probability of nine rats randomly expressing a synchronized estrous cycle
while nine other rats were randomly asynchronous is (0.2228 X 0.7789) or 6.19 X 10-7.
In conclusion, the data derived from these experiments suggest that, in female
rats, sustained consumption of a high-fat diet throughout adolescence and into adulthood
significantly reduces sensitivity to the psychomotor effects of 9-THC when compared to
female rats maintained on the control diet. Further, female rats maintained on the high-fat
diet were less sensitive to the changes in food intake caused by 9-THC than were female
rats maintained on the control diet. In contrast, relatively few differences in the
sensitivity to 9-THC were noted in male rats maintained under the same dietary
conditions throughout the same developmental period.
These findings raise questions regarding possible sex-differences in the
pharmacokinetics of 9-THC, as well as the relationship between dietary fats, sex
hormones and 9-THC. Further, it is not clear whether similar results would be seen in
female rats that began eating a high-fat in adulthood. The mechanism(s) by which highfat diets differentially alter sensitivity 9-THC across the sexes has yet to be elucidated
and the possibility of diet-related changes in endocannabinoid signaling must considered
in the light of these results. All of these topics represent possible future directions for
these studies.
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